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ABSTRACT 
Zidan Amani Z, Masters: 
June, 2017, Pharmacy 
Supervisor of Thesis: Dr. Nadir Kheir 
Title: Medication-Related Burden among Patients with Chronic Disease Conditions: 
Perspective of Patients attending Non-Communicable Disease Clinics in a Primary 
Healthcare Setting in Qatar 
This study aimed to adapt a medication-related burden instrument, the Living with 
Medicines Questionnaire (LMQ), into the Arabic context, report the psychometric 
properties of the Arabic version, and assess the burden resulting from the treatment of 
chronic conditions in Qatar.  
The research included two phases. In Phase 1; cultural adaptation was conducted to 
generate an Arabic version of LMQ (LMQ-AR). In Phase 2, the LMQ-AR was used in a cross-
sectional study among patients with chronic conditions in Qatar. Data obtained were used 
to assess the psychometric properties of the LMQ-AR, as well as to report medication-
related burden perceived by patients.  Construct validity of the LMQ-AR was evaluated by 
associating the LMQ-AR score with adherence, measured by the Adherence to Refills and 
Medications Scale (ARMS), and with global burden assessed by Visual Analogue Scale 
(VAS). Internal consistency was assessed using Cronbach’s Alpha. 
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A total of 293 patients with diabetes, from different ethnicities, age groups, and 
educational levels completed the study forms. Of the total sample, 138 patients used the 
Arabic versions. The domains of LMQ-AR showed acceptable internal consistency with 
Cronbach’s α ranging from 0.59 to 0.80. The overall LMQ-AR score was positively 
correlated with ARMS score (rs=0.400, P<0.0001), and VAS (rs=0.335, P<0.0001). Majority 
of the patients (n = 253) reported the existence of minimum (66.6%) to moderate (24.1%) 
medication-related burden. There was a moderate positive correlation between the 
scores of LMQ and ARMS, rs(251) =0.317, p < 0.0005. Diagnosis duration of diabetes 
(β = 0.203, p < 0.05), adherence score (β = 0.342, p < 0.05), marital status 
(β = 0.161, p < 0.05), employment status (β = -0.191, p < 0.05), and the presence of 
hypertension (β = -0.131, p < 0.05) were significant predictors of overall medication 
burden.  
The Arabic version of the LMQ is a reliable and valid instrument that can be used to assess 
medication-related burden among patients with chronic conditions in the Arabic context. 
A considerable proportion of patients suffer from medication-related burden, which 
could be affected by many factors. 
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Chapter 1: INTRODUCTION AND LITERATURE REVIEW 
1.1 The Burden of Non-Communicable Diseases 
Chronic, non-communicable diseases (NCDs), are those illnesses that are non-
infectious, non-transferable from one patient to another, and are most likely of lifelong 
duration with slow progression (1). Although most of the incidences of NCDs are 
preventable or manageable, NCDs are responsible for the global burden and increasing 
prevalence of morbidity and mortality (2). According to the World Health Organization 
(WHO)’s estimation in 2015, NCDs are responsible for 38 million deaths annually, a 
number that is higher than that from all other causes of deaths when combined (1). The 
majority of these deaths are considered premature (occur at less than 70 years of age) 
(1). The four major chronic diseases that cause 82% of the NCD deaths are cardiovascular 
diseases, cancers, respiratory diseases, and diabetes (1).  
Generally, many risk factors such as smoking, excessive alcohol consumption, 
unhealthy diet,  and physical inactivity contribute to the incidence and increasing 
prevalence of NCD conditions (1). There have been concerted global efforts aimed to 
reduce the burden of these diseases (1, 3, 4). For example, the United Nations (UN) has 
declared commitment to prevention and control of NCDs during the UN General Assembly 
in 2011 (4). Moreover, the WHO has designed and announced the Global Action Plan for 
the Prevention and Control of NCDs 2013-2020 that was endorsed by the 66th World 
Health Assembly in 2013 (3). This action plan contained nine voluntary global targets, to 
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which the Head of State members declared commitment, to reach a relative reduction of 
the top four NCDs related premature deaths by 25% by the year 2025 (3). The nine targets 
concentrated on reducing the risk factors associated with the NCDs (4).  The plan also 
offers a roadmap for collaboration between  the member states of the WHO, the private 
sector, and other organizations to achieve the mortality reduction target (3). The global 
efforts against NCDs also highlighted the importance of the primary care in early 
detection and management of the chronic diseases (1, 3). Despite all these efforts, the 
main focus of healthcare systems and clinical practice guidelines in general is to maintain 
clinical therapeutic goals for single conditions when managing chronic illnesses (5-7). This 
type of fragmented care approach would lead to diminished quality of life among people 
with multimorbidities (7)  
1.1.1 Multimorbidity and Polypharmacy 
Despite the increasing number of patients with multi-morbidity (the co-existence 
of two or more chronic diseases in one patient), healthcare systems, research, and usual 
practice focus heavily on the management of individual chronic diseases separately (7, 8). 
Many studies have shown that multi-morbidity is becoming progressively prevalent 
among patients with chronic conditions (8-10). In a retrospective study that used the 
medical records of 1,751,841 patients, Barnett et al. showed that multimorbidity does not 
only occur in older patients, but also those who were younger than 65 years (8). The 
literature also  demonstrated that patients with multiple chronic diseases utilize 
healthcare services more than patients with a single disease condition (11). Furthermore, 
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multimorbidity has been associated with lower quality of life and worse prognosis (12). It 
has therefore been suggested that more effective ways for  the management of multiple 
NCDs are needed, not only to improve the quality of life of the population, but also to 
reduce the economic pressures resulting from the emergence of new cases that place 
additional financial burden on the healthcare systems and the patients (9, 13). 
Furthermore, the achievement of intended clinical endpoints regarding each 
individual disease, requires complex treatment regimens and multiple medications, 
consequently subjecting patients to unneeded treatments (14). Developing effective and 
well-established strategies to address such situations requires careful attention to the 
balance between the desired therapeutic goals and the potential risks of such therapies  
(10). Bower et al. have qualitatively explored the perceptions of general practitioners 
(GPs) and nurses regarding the management and impact of multimorbidity (10). Their 
study revealed discrepancy between meeting clinical targets and patients’ expectations. 
This manifested mainly among patients attending multiple appointments to receive care 
focused on individual diseases. The investigators highlighted the challenges in the 
management of patients with multimorbidities due to lack of consultation time, which 
made patients overwhelmed by self-coordination of their care. (10). In concert with this, 
the recommendations in the literature are directed towards delivering patient-centered 
care, a model in which patients should be increasingly involved in the decision-making, 
and in coordination of their treatments (13). 
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The most common approach of the long-term management of chronic diseases is 
medication use (15). In fact, it is estimated that the use of medications in many countries 
represents a substantial portion of the healthcare expenditure regarding the 
management of NCDs (16, 17). The benefits of medications use in preventing premature 
deaths and the adverse consequences of NCDs, as well as managing associated 
symptoms, are indisputable (15). 
Polypharmacy, which is the use of four or more medications simultaneously by the 
same patient (13), could be perceived as an unavoidable evil of the advancement in the 
treatment strategies of today’s aging population (10, 13, 18). It is estimated that 
polypharmacy occurs in one out of every five patients taking regular medications, and in 
one out of every six patients who are 65 years or older (13). Several medications are 
prescribed for reasons other than treating the chronic conditions experienced by the 
patient only. Among other things, they might be prescribed but to prevent disease, 
promoting health, or to address other adverse consequences of the chronic diseases (18). 
Paradoxically, polypharmacy has also been associated with increased morbidity and 
mortality, hospitalizations, and demand for nursing home care (19, 20). Furthermore, 
polypharmacy has been shown to be the leading cause medication wastage (21, 22). In a 
study published in 2013, Krska et al. interviewed 21 patients attending primary care 
general practices in North West England regarding chronic medical conditions. The 
investigators reported patients’ concerns about the level of medication regimen 
complexity, and the difficulty in coping with the prolonged medication use. Their study 
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also reported the negative impact of medication therapy on the patients’ well-being (18). 
Polypharmacy can also result in drug-related problems (DRPs), such as non-adherence to 
medications, adverse drug reactions, and unnecessary drug therapy (18, 23-25). For these 
reasons, medication use related to the control or management of the NCDs is considered 
burdensome (16, 18, 25-27).  
The purpose of Pharmaceutical Care (PC), as described by Hepler and Strand, is to 
provide drug therapy for the purpose of achieving definite outcomes that improve the 
patient’s quality of life (28). This description that places the patient at the center of care, 
considers  the identification, prevention and resolution of DRPs  as the main 
responsibilities of a PC provider (28). Consequently, an effective PC practice, with its 
patient-centered philosophy and outcome-oriented tenets, should at least hypothetically, 
concentrate on enabling strategies that help the patients cope with their treatment plans, 
hence reduce the burden of therapy. 
1.1.2 Patients’ Experiences with Non-Communicable Diseases and Treatment 
Advanced medical intervention and technology has led to an increase in the 
number of patients suffering from chronic diseases and living longer with disability. This 
entails that more attention should be given to the patient’s role in their treatment plans 
(13, 29, 30).  
There have been several studies that evaluated the appropriateness of drug use 
process including; prescribing – intake – management (31-34). However, most of them 
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have focused on the clinical outcomes as a measure for medication appropriateness (33, 
35). On the other hand, many studies have also highlighted the importance of evaluating 
the treatment outcomes from the patient’s perspective (36, 37). Given that patients’ 
perspectives on issues related to the use of medicines are arguably different from those 
of healthcare providers, more attention has been drawn towards the appropriateness of 
drug therapy from the perspective of the patient in recent years (6, 18, 25). In their 
analysis of how NCDs are managed, May et al. argued that clinicians lack both the ability 
to identify and the strategies to manage the patient’s perceptions of barriers and 
problems associated with drug treatment. (30). Moreover, in a recently published book 
by Duncan and Blythe, there was a comprehensive explanation about multimorbidity and 
polypharmacy (13). The authors have shown that treatment burden can result from the 
traditional passive role of patients when utilizing health care where patients need to visit 
many healthcare providers to follow up their diseases individually. As an alternative to 
this model, they proposed the patient-centered care model, in which the patient needs 
to visit one experienced practitioner to manage his/ her multimorbidities (13). 
The traditional focus of clinical practice guidelines on individual diseases, the 
increasing coexistence of multiple comorbid conditions, and the lack of structured 
strategies to manage problems associated with the consequences of treatments meant 
that patients have to deal with extremely complex instructions and tasks associated with 
medications for the rest of their lives (38). Coping with adverse consequences of 
medications and having to tailor life activities according to the demands of the 
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therapeutic regimens result in putting extra burden on patients (6, 14, 39). For example, 
the quality of life of patients with diabetes can be affected by the estimated daily average 
time they spend on treatment and monitoring of their health. This effect was expressed 
by type 2 diabetes patients as equal to the suffering from nephropathy or neuropathy (6).  
The effect or burden of therapy can also be perceived differently by patients and 
healthcare providers (25). In 2002, Bernard et al. evaluated the credibility of the patients’ 
self-assessment of the adverse consequences of chemotherapy as compared to 
evaluation of the same consequences by the physicians, and the results emphasized the 
importance of putting much more weight on the evaluation from the patients’ 
perspective (40).  
1.1.3 Patient-Reported Outcome Measures 
Patient-reported outcome measures (PROMs) are those measures used to 
evaluate the health outcomes by the patients themselves (41). These measures are 
important in understanding and measuring the types of outcomes that affect the 
treatment regimens, as well as the life of the patients (42, 43). As the burden resulting 
from drug therapy is perceived by patients and cannot be quantified objectively, using an 
appropriate PROM is one of the best approaches given that these measures indicate the 
judgement of the patients about their treatment (15, 44). For this reason, there is an 
increased global interest in developing PROMs to determine the perceived burden of 
therapy among patients with chronic conditions in practice and research settings (6, 15, 
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25, 39, 45). Examples of these PROMS include the Treatment Burden Questionnaire 
(TBQ), the Patient-reported Outcomes Measure of Pharmaceutical Therapy for Quality of 
Life (ProQoL), and the Living with Medicines Questionnaire (LMQ). 
1.1.3.1 Development of Patient-Reported Outcome Measures  
Approaches used for the development and validation of PROMs are well-
established and well-documented in the literature (46). The development  process is 
usually iterative and of multiple steps (46, 47). The process starts with conceptualization 
of the overall objective using literature review of the subject matter, exploration of the 
views of the target population utilizing qualitative methodology, and formulation of a 
pool of items from which different domains are formed  (44, 47). Synthesis and piloting 
of the  scale is usually performed using expert opinions and a sample drawn from the 
target population (47).  
1.1.3.2 Validation of Patient-Reported Outcome Measures 
Validation, or assessment of the psychometric properties of newly developed 
measures, is an essential step that provides evidence for the validity and reliability of the 
new tool (or questionnaire)(46). As PROMs are subjective measures, and their results are 
therefore subject to bias, performing validation exercises prior to their formal utilization 
in research is of paramount importance. The three main psychometric tests typically 
performed in new measures are validity, reliability, and responsiveness.  
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Validity is generally a measure of the ability of the tool to measure what it is 
intended to measure. There are many types of validity, the most important being: (1) 
content validity, (2) construct validity and, (3) criterion validity (48, 49).  
Content validity is the degree to which the tool contains all the items and 
components representing the topic of interest. This is usually part of the initial 
development and validation of PROMs, and is assessed by gauging opinions of individuals 
with expertise in the area addressed by the measure (expert judges) (50).  
Construct validity examines whether the health measure relates to other 
measures in ways consistent with a plausible hypothesis  (49). Data from measures of 
other variables and from the measure being validated are analyzed for trends or patterns 
of hypothesized relationships, to determine if these hypotheses could be empirically 
confirmed (48). Construct validity is achieved if the trends are consistent with the 
hypotheses. Variables often used to test the pattern of relationships are health services 
utilization, clinical or objective measures, scores from another valid PROM, and 
medication use. Factor analysis is another strategy for assessing construct validity, and it 
is performed as part of testing a new tool to examine if a set of items in it are clustered 
in the same domain and the weight or bearing of items in different domains.  
Criterion validity, or predictive validity, refers to the empirical relationship 
between the measure and a reliable criterion with established construct validity, or with 
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an individual or a group of individuals with an established characteristic such as medical 
diagnosis (51).  
Reliability is the ability of the tool to produce consistent results. There are two 
main types of reliability testing: (1) test-retest reliability and, (2) internal consistency 
reliability. Test-retest reliability is the correlation of the results of the same questionnaire 
administered on the same respondents twice over time period. Typically, a reliable 
questionnaire would produce almost the same results. Conversely, internal consistency 
reliability, usually reported by Cronbach’s alpha, is a measure of the degree to which the 
items of a questionnaire underlying the same construct or domain, produce similar results 
(52). 
Responsiveness refers to the ability of the measure to indicate the change 
occurring to the target group of participants. This is usually assessed in longitudinal 
studies following patients over time and testing the change happening due to multiple 
reasons (intervention could be one of them) (53). 
Psychometric analysis is not restricted only to the development stages of a 
questionnaire or measure. Questionnaires are usually developed and validated among 
specific populations, and it is not uncommon for the new instrument to be used among 
different populations (39, 54-57). The instruments adapted from one population into 
another with different characteristics, should be further tested (54, 56). These tests 
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include cultural adaptation, cognitive debriefing, and, if necessary, validation exercises 
(39, 54, 58). 
The development, adaptation, and validation of the TBQ can be represented as an 
example of the aforementioned processes. The TBQ was developed in French, using 
literature review and qualitative work. The psychometric properties of the tool were then 
tested using factor analysis, construct validity (association with adherence, satisfaction 
measuring questionnaire, and complexity of regimen), and test-retest reliability (6). The 
validated TBQ was then translated and validated in English using internationally accepted 
procedures (39).  
1.2 Perceived Burden of Treatment 
The experience of utilizing health care, especially for long durations, is perceived 
differently among patients, and worth studying as a potentially critical threat to the 
success of treatment regimens (30, 59). This experience presents as “treatment burden” 
or “medication-related burden”, a concept that was defined only recently (14, 27, 45, 59, 
60). Treatment burden can be defined as “the overall workload imposed on the patients 
resulting from all aspects of utilizing healthcare, which has multiple negative effects on 
the patients’ wellbeing and quality of life” (14, 39). Treatment burden was reported to 
present a barrier to achieving the desired outcome of therapy (6, 25, 27). Like in the cases 
of polypharmacy and the associated complexity of treatment regimens, patients are at 
risk of the burden that accompanies the treatment of specific disease (40, 61-63). This 
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burden has been reported as non-adherence to prescribed medications (64), experiencing 
adverse effects of the medications (65), economic burden (66), impact on health-related 
quality of life (67, 68), and time spent on utilizing the treatment (68). 
In 2009, May and his colleagues proposed the term ‘Minimally Disruptive 
Medicine’ to represent a healthcare model that is about the effective use of health 
services designed to achieve the therapeutic goals with respect to the patients’ capacity 
(30). They explained that being a patient means suffering from not only the illness and its 
consequences, but also from the effects of healthcare utilization and its consequences 
(30). They argued that patients are often exposed to a fragmented healthcare system, 
and they try to cope with multiple recommendations and complex drug therapy regimens 
(especially if they have multimorbities). The investigators suggested that patients try to 
adjust their lives according to the requirements of their treatment plan. All that workload 
imposed on the patients, in addition to the economic burden of utilizing healthcare in 
some instances, constitute what they termed “Treatment Burden” (30).  
1.2.1 Terms Associated with Perceived Burden 
Although the term “treatment burden” describes the overall burden the patient 
experiences from utilizing health care (6, 45, 59, 62), in earlier works, this term was used 
to describe the adverse clinical outcomes of different treatments (40), satisfaction with 
therapy (69), poor adherence to drug therapy as measured by pill counts (70), or impact 
on quality of life (67, 68). The published literature described the burden perceived by 
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patients mainly from using medications as “medication burden”, or “medication-related 
burden” (15, 18, 25, 60). Literature also described the term “patients’ lived experience 
with medicines” to describe individuals’ experience of this burden and its impact on 
beliefs, behaviors, and wellbeing. However, a closer look at the literature that described 
these terms, showed that medication burden frameworks also contained similar aspects 
as explained by treatment burden. In recent systematic reviews investigating medication-
related burden, the literature describing treatment burden were all included in the 
analyses (15, 60). Hence, the terms “treatment burden”, “medication burden”, and 
“patients’ lived experiences with medicines” are used among scholars interchangeably to 
describe almost the same aspects of the perceived burden. In this thesis, “medication-
related burden” is used to describe the perceived burden resulting from the overall 
treatment process (including therapies and other aspects associated with managing 
chronic health conditions). 
1.2.2 Classification of Literary Works of Medication–Related Burden 
The work by May et al. in 2009 triggered discussions among researchers trying to 
agree on a better understanding of this term as it was critical for the delivery of tailored 
interventions (30). Qualitative studies and systematic reviews were performed to better 
understand the views of patients as well as the impact and the predisposing factors of 
this burden (60). There are also published studies about developing tools to measure 
burden related to therapy from the patient perspective (6, 25, 39, 71). In addition, the 
literature suggests that prolonged medications use constitutes a major challenge that 
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impacts on patients’ coping ability with treatment regimens, and hence worsens 
medication burden (15, 18, 25) 
The following is a summary of the literary works that explained, and facilitated, 
the measurement of medication-related burden: 
1.2.2.1 Qualitative Studies 
- Montori and colleagues published a qualitative study, in which they investigated 
the treatment burden as a subject of discussion between patients and physicians during 
diabetes follow up visits. They found that less than half of the monitored visits contained 
discussions about treatment burden, with only 30% of them precisely mentioning 
treatment burden. Those discussions demonstrated some aspects of treatment burden 
like access to treatment, administrative burden, treatment consequences, and 
monitoring of the process (72).  
- In order to build a framework to inform measurement of treatment burden, Eton 
et al. conducted two qualitative studies. First, they conducted semi-structured interviews 
among patients with at least one chronic condition and who had complex regimens to 
follow. Data resulting from these interviews were used to formulate a framework and 
themes describing treatment burden. These themes included: (a) the workload imposed 
on patients, (b) the strategies needed to self-care, and (c) the factors that magnify the 
perceived burden, and these themes were further detailed into six subthemes.  Later in 
2015, Eton’s research team published an article about refining their framework using 
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semi-structured interviews with their previous study sample, in addition to new cases 
from different health institution to account for differences in utilization of different 
healthcare services. They also used four focus groups in this study in order to confirm the 
structure of the emerging framework. The final framework contained a sub-theme of 
barriers to self-care under the main theme “factors that exacerbate treatment burden”. 
Moreover, the “impact of treatment burden” main theme was added to quantify the 
exhaustion patients experience as a result of treatment burden  (45). 
- Through a qualitative study that used interviews with patients taking more than 
four medications regularly, and aimed to identify issues related to prolonged medication 
intake, Krska et al. highlighted eight themes representing aspects of medication burden: 
“relationships with health professionals”, “practicalities in using medications”, 
“information about medications”, “efficacy of their medications”, “side effects”, 
“attitudes”, “impact of the perceived burden” and “control or autonomy” (18). 
- Sav et al. published results of an in-depth analysis of the qualitative data collected 
from a large sample of patients (n= 97) with chronic conditions or their carers regarding 
treatment burden. They found out that treatment burden is a multidimensional concept 
of cyclic nature that contains subjective and objective elements. The elements that 
emerged from this study were: “financial burden”, “time and travel burden”, “medication 
burden” and “healthcare access burden”. These elements were considered predisposing 
factors that can cause treatment burden, and as consequences resulting from that 
perceived burden (27). 
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- Sav et al. also published a qualitative study that explored the patients’ treatment 
burden from the perspective of the Australian consumer health organizations. Those  
organizations are responsible for representing and providing help for patients with 
chronic diseases or their carers (26). During the interviews with key informants in these 
organizations, the investigators explored main factors of treatment burden. Medication-
related burden was the main factor, followed by the burden perceived by the carers, time 
spent on treatment, financial burden among the low income people, and the burden 
resulting from fragmented healthcare system (26). 
1.2.2.2 Quantitative Studies 
There is paucity of quantitative studies with the main focus of evaluating 
perceived overall treatment or medication-related burden. The following is a brief 
description of some quantitative studies highlighting burden from the perspective of the 
patients: 
- There have been studies that assessed burden of therapy as part of quality of life 
measures among patients with specific chronic diseases. For example, the cystic fibrosis 
questionnaire (a disease-specific quality of life measure) contains a domain that measures 
perceived treatment burden. This was subsequently used in many studies to assess 
perceived burden as part of quality of life (67, 73, 74). 
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- Treatment burden was also reported as part of assessing psychological distress 
resulting from diabetes management. This was reported as diabetes distress (75, 76), 
quality of life (77), signs of depression (75), or emotional burden(78). 
- Moreover, time to treat side effects of chemotherapy, and loss of working days 
were measured and reported as treatment burden among cancer patients (61). 
- In 2016, a study with the main focus of measuring the overall treatment burden 
from the perspective of patients with chronic conditions in Australia, was published. This 
work indicated that a considerable proportion of patients in Australia suffers from burden 
resulting from treatment regimens. It also showed that age, the existence of carer, and 
having endocrine health conditions (like diabetes) are considered predictors of treatment 
burden (79).  
1.2.2.3 Systematic Reviews 
- In 2013, Eton et al. published a systematic review of the PROMs used to evaluate 
treatment burden of three chronic diseases (diabetes, nephropathy, and heart failure) in 
order to inform the development of generic measure for chronic conditions (44). They 
identified 57 PROMs, majority of them (82%) were assessing burden resulting from 
diabetes care, and only 15 PROMs were developed using patients’ perspectives. The 
common domains across all the measures were 12 accounting for all aspects of treatment 
or medication burden: 1) Distress resulting from regimen, 2) Scheduling flexibility, 3) 
Family conflict, 4) Side effects of medications, 5) Appropriateness of treatment, 6) Dietary  
burden, 7) Self-care convenience, 8) Overall treatment burden, 9) Monitoring/workload 
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burden, 10) Device use burden, 11) Lifestyle changes or activity restrictions, 12) Economic 
burden (44).  
- Mair et al. published a systematic review of the qualitative research that 
investigated the perceived burden resulting from treatment of stroke (38). As a result of 
this work, they formulated a framework of the components of the treatment burden 
associated with stroke management (38). Their findings, although restricted to stroke, 
were, as hypothesized by the investigators, in line with the elements of the concept of 
treatment burden. 
- Sav et al. published a systematic literature review to analyze the concept of 
treatment burden (16). In their study, and in an effort to reduce the treatment burden, 
they demonstrated that the main consequences of treatment burden are failure of 
treatment plans leading to poor health outcomes and imposing burden on others. The 
predisposing factors they highlighted in the study were comorbidities, age, gender, and 
family circumstances of the patients (16). 
- Recently, in 2016, Katusiime et al. published a systematic review, in which they 
summarized the evidence from the literature regarding the developed PROMs measuring 
medication burden, and their psychometric properties (15). They concluded that there 
was no specific tool that measures all the aspects of treatment or medication burden. 
Among the 15 tools identified, nine were multidimensional (covering many aspects of 
medication burden), and six were unidimensional. These measures varied in development 
and validation approaches. The overall domains covered by the questionnaires were 
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treatment related quality of life, availability and accessibility of medicines, self confidence 
in using medicines, control of treatment regimen, treatment and/or medication related 
burden, issues related to adherence or follow up, beliefs, perceptions, attitudes, general 
satisfaction, impact on the life of patients, relationship with healthcare providers, 
effectiveness, management, and knowledge of using medicines (15). 
- Similarly, in 2016, Chen et al. published a systematic review and metasynthesis 
which used the published qualitative studies investigating treatment burden, medication 
burden, or patients’ lived experiences with treatments; regardless of the specific cases or 
chronicity of the diseases (n=34). They used this pool of data to formulate a model, that 
could be used later to develop a comprehensive tool for the measurement of medication-
related burden (60). This model contained three domains that explained the problems 
related to medication use: “Medication-related problems”, “Medication-related beliefs”, 
and “Medication taking practices”. Within the 13 subdomains, the authors explained the 
relationship between the three domains as the first two domains affect each other, and 
subsequently affect the third one (practices of medication intake) leading to the ultimate 
effect on the success or failure of the therapy (60).  
1.2.2.4 Questionnaires Developed and Validated and/or Adapted 
Below is a description of the developed tools with a focus on medication and/or 
treatment burden. 
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- In 2012, the Treatment Burden Questionnaire (TBQ), a tool that measures the 
treatment resulting from therapy regardless of the health condition being managed, was 
developed and validated in France. The development was based on literature review and 
expert opinions. In their article, the researchers described the psychometric properties of 
the TBQ determined through factor analysis and construct validity (6). This tool was then 
adapted into the English language and subjected to validation testing, demonstrating 
similar psychometric properties to the original tool (39). 
- Sakthong et al. published a study about the development and validation work of 
an instrument measuring medication management.  Their multidimensional tool, Patient-
reported Outcomes Measure of Pharmaceutical Therapy for Quality of Life (PROMPT-
QoL), was intended as a health-related quality of life measure. The instrument contained 
10 domains measuring many aspects of medication burden besides the overall QoL (71). 
- Finally, the Living with Medicines Questionnaire (LMQ) was developed and 
validated in English to measure the burden resulting from prolonged use of medicines 
among patients with chronic diseases. The tool includes eight domains covering wide 
range of issues regarding the impact of medicines’ use on the lives of the patients. The 
authors demonstrated the novelty of their work as the tool’s statements were derived 
entirely from patients’ perspective (25).  
1.2.3 The Relationship between Perceived Burden and Treatment Plans 
A plethora of literature has described treatment or medication burden, and 
highlighted the association of this burden with adherence to medication therapy (6, 14, 
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25, 60). As nonadherence is considered a critical issue affecting outcomes that matter to 
patients, the effect and magnitude of treatment burden on adherence is worth further 
assessment.  
The level of adherence to drug therapy among patients with specific health 
conditions could be affected by the magnitude of treatment  burden (80). Some aspects 
of treatment burden (economic, administrative burden, knowledge) were described as 
barriers to proper self-management of multimorbidity (81).  
In reviews aiming to describe the factors that complicate patient care, non-
adherence was considered a possible negative outcome associated with excessive 
workload imposed on the patients (82). Systematic reviews and metasynthesis of 
qualitative studies, or concept analysis, also focused on the association between non-
adherence and perceived treatment burden (16, 38, 60). Pill count or prescription burden 
was also found to be associated with adherence and clinical variables of the disease (40, 
63, 70, 83). 
Further, the impact of treatment burden on patients’ lives was well demonstrated 
in several qualitative studies. These studies explained that patients’ commitment to 
treatment regimens and quality of life were hindered by suffering from aspects of utilizing 
healthcare (14, 27, 45, 59, 67, 72). 
The literature also reported that validation studies measuring treatment burden 
provided evidence that burden was indeed associated with adherence scores. In the 
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validation of both the French and English versions of TBQ, high treatment burden was 
found to be associated with low adherence to prescribed medications (6, 39). 
Although the concept of treatment burden is attracting greater attention from 
various research groups, studies with main focus of associating treatment burden with 
adherence to therapy are scarce, mainly qualitative, and are investigating specific 
diseases (83, 84). 
1.3 Non-Communicable Diseases Prevalence and Management in Qatar 
The growing prevalence of NCD is affecting all countries around the world. The 
proportion of people living with NCDs is increasing in the developed countries, with the 
increase in risk factors for these illnesses like poor diet and inactive lifestyle (85). 
Moreover, although the prevalence of NCDs is higher in low and medium income 
countries (1), wealth can also be associated with increasing risk factors for NCDs (85). 
According to the World Bank classification, Qatar is considered as a high-income country 
(86). In 2014, NCDs were estimated to cause 69% of the deaths in Qatar (87). Of these, 
cardiovascular diseases were responsible for the highest proportion of the deaths (24%), 
followed by diabetes (19%), and cancers (18%) (87). These three NCDs forming a health 
priority in Qatar, share similar risk factors including tobacco use, obesity, inactive lifestyle 
and poor diet (88). NCDs are also associated with significant economic burden in Qatar. 
Knowing that the total direct and indirect cost associated with cardiovascular diseases, 
mental disorders, cancer, respiratory diseases, and diabetes management was $36.2 
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billion in 2013 in the Gulf Cooperation Council; it was estimated that spending per head 
of the population in Qatar will reach about $2,778 by 2022 (85). 
 To the best of our knowledge, there are no available estimates of the 
multimorbidity or polypharmacy associated with chronic NCDs in Qatar. However, as 
these are usually associated with increasing prevalence of patients with NCDs (8, 13), one 
can assume their presence among patients with NCDs in Qatar. 
The major primary health care provider in Qatar is Primary Health Care 
Corporation (PHCC). This corporation includes 21 primary health centers that are 
distributed throughout the State of Qatar to maintain the population’s health and prevent 
diseases. The health services provided by PHCC include the management of NCDs, 
through dedicated NCD clinic(s) in each health center (89). According to PHCC annual 
statistics, in 2014, the total number of registered NCD visits was 17318, with 78% of these 
visits due to diabetes (90).  
1.3.1 Health Care Services Provided by Primary Health Care Corporation in Qatar 
The global recommendations regarding the management of chronic 
multimorbidities highlight the need to establish primary care clinics where patients can 
visit regularly a GP to follow up their multiple conditions (13).  
The Qatar’s National Health Strategy, designed and published by the Supreme 
Council of Health (now the Ministry of Public Health), declared the establishment of a 
world-class healthcare system among its priority goals. The aim is to provide a 
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comprehensive primary care model that puts the patient at the center of care (91). 
Further, the Qatar National Primary Healthcare Strategy aimed to provide high quality 
care, reduce barriers, and maximize the efficiency of provided services (92).  Moreover, 
the management of the NCDs among the PHCC clinics was established using the evidence-
based Chronic Care Model, which empowers the role of the patient in the success of 
treatment regimens (89, 93). NCD clinics that provide usual management and follow up 
for patients with chronic diseases in Qatar are distributed across the country (89). 
Providing the health services in these centers; which include follow up, laboratory tests, 
and supply of medications at an affordable costs; is part of the Social Health Insurance 
Scheme offered for all people in Qatar (94). This Scheme aimed to provide basic 
healthcare services to citizens and residents in the country (94). The aim and strategies 
of the primary care services provided for the NCD patients in Qatar resemble the 
recommended transition in health care globally, as well as the plans and strategies that 
are aimed at reducing the mortality and burden related to the NCDs.  
1.3.2 Rationale of the Study 
It has been shown that measuring medication-related burden as perceived by the 
patients is important as a key step to designing and delivering minimally disruptive 
medicine to NCD patients (30). Polypharmacy, non-adherence to treatments, and the 
consequences of failures of treatment plans not only affect the life of patients, but also 
lead to increased economic and social burden on the society as a whole (13). 
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As Qatar’s healthcare system is aimed at providing world-class services, it is 
important to identify any existing or potential barriers to the achievement of its target 
goals and primary mission. Hence, assessment of the medication-related burden, from 
the patient perspective is an important endeavor to inform the National Health Strategy 
of any barriers that may hinder the optimum use of health services at the primary health 
care level. 
In recent years, PROMs have been developed and validated to measure 
medication-related burden (25, 39, 71). Given that the development and validation of 
these tools were done in environments that differ from Qatar (15), it is pertinent to adapt, 
and to determine the psychometric properties of any tool before its use in Qatar’s 
population. 
Moreover, previous studies have reported the association between perceived 
medication-related burden and the patients’ well-being as well as adherence to therapy. 
To our knowledge, this association has not yet been measured quantitatively among 
patients with NCDs. 
1.3.3 Aim and Objectives of the Study 
The aim of this study was to assess the burden resulting from the treatment of 
chronic NCD conditions in Qatar and its impact on medication adherence. To achieve this 
aim, the following specific objectives of the study were set: 
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1. To identify a tool that measures medication-related burden from patients’ 
perspective and to adapt it into the Arabic context. 
2. To determine the psychometric properties of the tool adapted into Arabic. 
3. To assess the burden of medication therapy from the perspective of patients with 
chronic NCD conditions in Qatar. 
4. To investigate the magnitude of the association between medication-related 
burden and the self-reported adherence to prescribed medications. 
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CHAPTER 2: METHODS 
The research was performed in two phases. In Phase 1, a literature search was 
performed to select a tool that measures medication-related burden, followed by cultural 
adaptation to generate an Arabic version of the tool. In Phase 2, the adapted tool was 
then used in a cross-sectional study among patients taking multiple medications for 
chronic NCD conditions in Qatar. Data obtained from this study were used to assess the 
psychometric properties of the adapted Arabic version of the medication-related burden 
questionnaire. Medication-related burden perceived by patients and the impact of this 
burden on adherence to drug therapy among the cohort of patients was reported. The 
study also looked into the patient-related variables that could have bearing on the 
medication-related burden. 
2.1 Phase 1: Selection and Adaptation of a Medication-Related Burden Questionnaire 
2.1.1 Selection of a Medication-Related Burden Questionnaire 
Only a few self-administered questionnaires have been found in the literature, 
which were developed to measure patients’ perceived medication-related burden (6, 25, 
71). For this research, the following criteria were considered as a guide to selecting an 
appropriate tool to be used among our cohort of patients: 
a. Comprehensiveness: The questionnaire must be comprehensive and should 
include a wide range of areas associated with burden expressed by patients through well-
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conducted research. The burden must be related to the problems that may face patients 
receiving primary healthcare in NCD clinics. 
b. Development process: The questionnaire must have been developed utilizing 
best practices and evidence-based processes. 
c. Psychometric properties: The questionnaire has to document an evidence of 
appropriate psychometric properties generated through robust validation studies.  
Based on the above criteria, three questionnaires that were developed for the 
purpose of assessing perceived burden were identified through the literature search and 
examined to assess their suitability for use in this research. The original developers of the 
three questionnaires were contacted by the researchers who explained the objectives of 
the present study and requested access and permission to adapt and use the full 
questionnaires.   
Description and characteristics of the identified tools are summarized in table 1 
below. 
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Table 1. Characteristics of the Identified Tools Measuring Treatment or Medication-Related Burden 
 TBQ* ProQoL** LMQ*** 
Country and 
language 
France - French (6) Thailand – Thai (71) United Kingdom – English (25) 
Other languages English (39) - - 
Structure of 
items and 
response 
choices 
The English version contains 15 
items for which the respondents 
indicate their rating of the items 
being a problem using a numbered 
scale (from 0 indicating not a 
problem, to 10 indicating a big 
problem). Global score is the sum of 
the items’ scores. The tool measures 
the patients’ difficulties regarding 
medication management, follow-up, 
lifestyle changes, administrative 
tasks and regular healthcare (6, 39). 
Contains 9 domains measuring 
aspects of medication 
management, medication use, and 
its consequences, besides the 
overall quality of life, with 43 items, 
each having 4-5 response choices 
(71). 
Constituting 8 domains, the tool 
contains 41 statements to which the 
respondents indicate their level of 
agreement using a five-point Likert-
type scale (from strongly agree, to 
strongly disagree). In addition, there 
is a free text (open-ended) question 
allowing the patient the freedom to 
add any other relevant issues. LMQ 
also contains a visual analogue scale 
(VAS), through which the 
respondents provide an overall 
evaluation of perceived medication-
related burden using a scale of 0 (no 
burden at all) to 10 (extremely 
burdensome) (25). 
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Psychometric 
properties 
The psychometric properties of the 
tool were evaluated among 610 
patients with chronic conditions, 
and included; factor analysis, 
reliability analysis (Cronbach α of 
0.90), and construct validity 
(correlation with clinical variables, 
adherence to medications measured 
by Morisky’s Medication Adherence 
Scale, quality of life assessed by 
PatientLikeMe Quality of Life Scale, 
and patients confidence in their 
knowledge of conditions and 
treatments) (39). 
The psychometric properties were 
evaluated among patients with 
chronic conditions in Thailand, and 
included practicality (i.e., 
administration time, missing data, 
and floor/ceiling effects), reliability 
(i.e., internal consistency and test-
retest), and validity (confirmatory 
factor analysis and known-groups, 
convergent, and criterion validity) 
(71). 
Explanatory factor analysis (EFA) and 
confirmatory factor analysis (CFA) 
were performed among patients in 
the UK and Australia. The CFA (with 
discriminant and convergent 
validity) suggested that the items 
gave a reasonable fit to data. The 
testing of the subscales also resulted 
in reasonable psychometric 
properties with the domains 
affected by pharmaceutical care 
interventions (95). 
Consensus of 
the research 
team regarding 
the selection of 
a tool 
The research team found that this 
unidimensional tool would not be 
sufficient to capture existing burden 
among our cohort of patients. Since 
the services provided by NCD clinics 
are provided free of charge or at 
minimal cost, and are aimed for all 
After closely studying the English 
version provided by the developers, 
the research team judged that the 
English translation had serious 
issues that interfere with 
understanding of the intended 
meaning of the tool’s items; some 
The LMQ is a valid tool, and covers 
many aspects of the burden that 
patients with chronic conditions may 
face. It needed to be adapted into 
our context before its use 
(Appendix A). 
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the population without complicated 
fragmentation in utilizing the care, 
administrative and practical issues 
measured by TBQ would not reflect 
the burden patients in our study my 
suffer from (89). 
questions were two tailed, and the 
leading question of some items 
misleads the respondents. There 
were also no studies in its English 
version that contain linguistic issues 
which may prohibit its ability to 
assess burden in our setting. 
* Treatment Burden Questionnaire 
** Patient-reported Outcomes Measure of Pharmaceutical Therapy for Quality of Life 
*** The Living with Medicines Questionnaire 
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From the three tools identified, the Living with Medicines Questionnaire (LMQ) 
was selected based on the above mentioned criteria. The LMQ contains 41 statements 
with which respondents are required to indicate their level of agreement using a five-
point Likert-type scale (from strongly agree, to strongly disagree). In addition, a free text 
(open-ended) question accord the respondent the opportunity to add any other relevant 
issues that were not covered in the questionnaire. The tool comprised of eight domains: 
Relationships with health professionals, Practicalities, Information, Efficacy, Side effects, 
Attitudes, Impact, and Control. A visual analogue scale (VAS) that allowed the respondent 
to express his/her overall perceived medication burden on a scale of 0 (no burden at all) 
to 10 (extremely burdensome) was also included. 
 
2.1.2 The Translation and Cultural Adaptation Process of LMQ 
The guidelines developed by the International Society for Pharmacoeconomics 
and Outcomes Research (ISPOR) for adaptation, validation, and translation of 
questionnaires related to measurement of patient-reported outcomes (PROs) were 
utilized in this study (56). Figure 1 provides a flow diagram summarizing the multistep 
process and outcomes of each stage in the development of the Arabic version of the LMQ. 
 33 
 
 
Figure 1. Flow diagram of the process followed in developing the Arabic version of LMQ 
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Preparation: Permission to use the LMQ was obtained from the original 
developers of the questionnaire. A comprehensive study protocol, which contained 
detailed information about the design, methods, and expected results of the project was 
developed and shared with the developers. The developers provided details and 
explanations as needed throughout the process of the Arabic questionnaire adaptation.  
Forward translation: Two translations of the LMQ from English to Arabic were 
conducted by two independent, bilingual, and qualified translators. The translators, who 
were experienced in translating PROs, were not informed about the content of the tool 
prior to the translation process. 
Reconciliation: A panel comprising three study investigators (two of whom are 
fluent in English and Arabic) and the translators was convened on several occasions to 
develop a single Arabic version of the LMQ translations. This was done to eliminate any 
discrepancies in translation, and to ensure cultural equivalence of the tool between the 
original and target populations. This generated the first reconciled Arabic version of LMQ. 
Back translation and review: The first reconciled Arabic version of LMQ was back 
translated to English by a third independent, bilingual and qualified translator who was 
not familiar with the original English version of LMQ. This new English translation was 
compared to the original LMQ by the study investigators to test the quality of the 
translation and to ensure that the intended meanings of all items were maintained. A 
review of the outcome of this step led to further refinement of the Arabic questionnaire 
and to the second reconciled Arabic version. According to the ISPOR guidelines, this step 
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should be followed by a step of ’harmonization’. Harmonization is recommended when 
the tool of interest is translated into more than one language, in which different versions 
are compared to ensure equivalence between them. However, this was not the case in 
the current work. 
Cognitive debriefing and review: A group of seven people was purposively 
selected for cognitive debriefing. These Arabic speaking participants were selected to 
obtain representation of a balanced gender, age, educational level, and nationality. While 
the purpose of this step is to ensure that the developed Arabic version is comprehensible 
to the general population, the majority of the selected participants had at least one 
chronic condition. Through one-to-one interviews, they provided feedback on the second 
reconciled LMQ Arabic version in areas related to comprehension, time burden, and 
acceptability. Discussions during review of the cognitive debriefing process resulted in 
refining the changes made in the previous steps pertaining to cultural and linguistic issues. 
The cognitive debriefing process also allowed investigators to assess the acceptability of 
the content of the original LMQ, and to communicate this to the developers of the original 
version.  
Proofreading and final report: The Arabic version of the LMQ was revised carefully 
by the study investigators to produce the final translation (called LMQ-AR) (Appendix B). 
A final report regarding the original LMQ and the Arabic translation, the methods used to 
generate the translated version and the findings arising during the linguistic validation 
process was generated and shared with the LMQ developers. 
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2.2 Phase 2: Measurement of Medication-Related Burden among Patients with Non-
Communicable Diseases 
2.2.1 Ethical Considerations and Approval 
Ethical approval to conduct the study was granted by the Research Section 
(Clinical Affairs) of the PHCC (approval no. RC Ref. PHCC/RC/15/10/015). Ethical 
considerations and principles in line with the requirements of research involving human 
subjects were followed. An informed consent was obtained from each patient prior to 
enrolment into the study and confidentiality of the patients’ information was guaranteed 
by the research personnel. 
2.2.2 Study Design 
A cross-sectional quantitative study using a self-administered, and adapted 
questionnaire was conducted to measure perceived medication-related burden and 
medication adherence among patients with chronic NCD conditions in Qatar.  
2.2.3 Study Setting 
Primary health care services in Qatar are provided by the PHCC through 21 primary 
health centers that are intended to cover almost all of the population as part of the 
National Health Strategy (91). PHCC, through the NCD clinics of the health centers, offers 
disease management and regular follow up for the largest number of patients with 
chronic disease conditions in Qatar. In 2014, the number of visits to PHCC clinics was 5.2 
million (89). For this research, three centers (Mesaimeer, Airport, and Omar Bin Al-
Khattab Primary Health Centers) were selected. The selection of the clinics was based on 
the ethical approval conditions and the approximate similarity in demographic 
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distribution of patients’ visits across the health centers and based on the fact that all the 
three centers provide NCD services (89).  
2.2.4 Study Population 
Medication-related burden is extensively reported in the literature to be an issue 
among patients with chronic disease conditions, which leads to a negative impact on 
adherence to treatment plans (60). For this reason, the target population was patients 
with chronic disease conditions attending NCD clinics at PHCC centers for regular follow 
up. Although the perceived burden is expected to be associated with seeking treatment 
for any chronic illness (60), patients in this study were recruited if they have diabetes 
mellitus (DM), with or without comorbidities (other NCDs). DM can be considered a 
representative example of patients living with chronic conditions, and an NCD of priority 
in Qatar due to its high prevalence. Other chronic disease conditions usually co-exist with 
DM and may affect the success of its management. These common comorbidities include, 
but are not limited to, obesity, hypertension, dyslipidemia, other cardiovascular diseases, 
chronic kidney disease, depression, and sleep disorders (96). According to the statistics 
report published by PHCC, 78% of the visits to the NCD clinics in Qatar in 2014, were by 
patients with diabetes (90). 
2.2.5. Participants and Eligibility Criteria 
Patients were eligible for enrollment in the study if they were at least 18 years of 
age, diagnosed with diabetes for at least 6 months prior to the study (with or without 
comorbidities), and able to communicate in English and/or Arabic. Patients were excluded 
from the study if any of the following criteria was met: inability to communicate in English 
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or Arabic, documented mental disabilities, having any speech impairment, or pregnant 
women. 
2.2.6 Sample Size 
Sample size was aimed to be representative of the target population (i.e. patients 
with diabetes in Qatar). It was calculated using the following equation (97): 
 
                          Sample size = 
Where Z1-a/2 is standard normal variate, which is 1.96 at 5% level of confidence 
and P is the expected proportion in the population. In the current study, P is the 
proportion of the patients with diabetes, who suffer from medication-related burden in 
Qatar. According to the International Diabetes Federation, 13.5% of the population in 
Qatar has diabetes (98). As the proportion of the patients with diabetes who suffer from 
medication-related burden is not known, we assumed that burden could be perceived by 
all patients. For this reason, the P of this equation was estimated as 0.135 (expected 
proportion of the diabetes patients in Qatar i.e 100% of the 13.5%) to calculate the sample 
size of this study. Assuming an absolute error (d) to be 0.05, the minimum sample size 
required for this study was 180 patients. This number increased by 30% to account for 
missing data. Hence, a total of 234 patients was the target for this study. 
2.2.7 Sampling Technique 
Although random sampling technique is warranted in such a study in order to draw 
an unbiased sample (99), this was not feasible in the setting of the current study. NCD 
(Z1-a/2)2 P (1 – P) 
d2 
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patients are given scheduled 20 minutes follow up appointments with physicians. As each 
of them arrives consecutively for their appointments, it was not feasible to have all of 
them screened together (obtaining a sampling frame of eligible patients), and to draw a 
random sample among them. For this reason, convenient sampling was used, in which 
patients were screened for eligibility upon their arrival to the clinic using electronic 
medical records. Eligible patients were then approached to participate in the study. Those 
who consented to participate were enrolled in the study. 
2.2.8 Outcome Measures  
The primary outcome measure was the self-reported medication-related burden 
(including LMQ score and the VAS score). Self-reported adherence was assessed as a 
secondary outcome measure. Additionally, the data collected using the designed data 
collection form were used as variables to be associated with the main outcome measures. 
Medication-related burden was measured using the LMQ, while self-reported adherence 
was measured using the Adherence to Refills and Medications Scale (ARMS) (100). 
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2.2.9 Study Instruments 
The following were the instruments used in the study: 
1. The Living with Medicines Questionnaire (LMQ), validated in English (95), and adapted 
into the Arabic context during Phase 1 of this research (101). Both the Arabic and the 
English versions were used in this research, as applicable (Appendixes A&B). 
2. The 12-item Adherence to Refills and Medication Scale (ARMS) (100), validated in 
English, and translated into the Arabic context by the research team and in coordination 
with the original developers of the tool. ARMS was developed to measure adherence to 
drug therapy and was validated among patients prescribed long-term therapy for 
coronary heart diseases. The scale demonstrated a high internal consistency reliability 
(Cronbach’s α=0.814) and a significant correlation with Morisky Adherence Scale 
(Spearman’s rho =-0.651, P < 0.01) (100). Both the Arabic and the English versions were 
used in this research, as appropriate (Appendixes C&D).  
3. A data collection form was also designed and piloted for use in this research. The 
variables collected included: demographic information (age, gender, country of origin, 
marital status, and education level), smoking history, and clinical information (diagnosis 
of DM, disease duration, comorbidities, prescribed medications, BMI, lifestyle changes, 
and clinical indicators of the disease). This information was elucidated through patients’ 
interviews and/or from electronic medical records. 
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2.2.10 Data Collection Procedures 
Eligible patients were met during their regular follow up visits to the NCD clinics 
at the health centers. The researcher approached the patient to introduce herself, 
provided information about the study, and obtained informed consent to participate in 
the study. The questionnaires were then self- or interviewer-administered depending on 
the patient’s preference or literacy level. Other patient-related information were then 
obtained from the electronic medical records as needed using the data collection form 
that was specifically designed for this project. 
 2.2.11 Data Analysis  
Phase 2 of the study (the cross-sectional quantitative study) resulted in data, for 
which the analysis plan was designed as follows.  
2.2.11.1 Study Variables 
Table 2 illustrates the variables collected from the medical records and from the 
patients for the purpose of data analysis. Selection of the variables (socio-demographic, 
and clinical) was based on previous studies indicating possible association of each variable 
with perceived medication-related burden. 
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Table 2. The Variables Used in the Data Analysis of Phase 2 
Variable Measurement 
type 
Variable expressed as Source of 
data 
Socio-demographic variables 
Age Continuous Years Medical 
records 
 Categorical - Up to 65 years 
- Over 65 years 
 
Gender Categorical - Male 
- Female 
Medical 
records 
Country of origin Categorical - Qatari 
- Non-Qatari 
Medical 
records 
Ethnicity Categorical - Arab (Qatari) 
- Arab (Non-Qatari) 
- Asian (Indian Subcontinent) 
- Asian (Philippines) 
- Others 
Medical 
records 
Marital status Categorical - Married 
- Single 
-Divorcee 
-Widowed 
Patient 
Education level Categorical - Less than primary school 
- Primary school 
-Middle school 
- High/ or secondary school 
- Technical college 
- University degree 
- Post graduate degree 
Patient 
Lifestyle changes Categorical - None 
- Exercise 
- Healthy diet 
Patient 
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- Heathy diet and exercise 
Employment Categorical - Employed 
- Unemployed 
- Retired 
- Full-time student 
Patient 
Smoking history 
Cigarette smoking Categorical - Current smoker 
- Former smoker 
- Never smoker 
Patient 
Shisha smoking Categorical - Usual shisha smoker 
- Social shisha smoker 
- Former shisha smoker 
- Never shisha smoker 
Patient 
Clinical variables and medications 
Diagnosis duration Continuous Years Patient 
HbA1c Continuous Percentage  Medical 
records 
Control of DM Categorical - Uncontrolled DM (HbA1c > 7%) 
- Controlled DM (HbA1c ≤ 7%) 
Medical 
records 
Number of prescribed 
medications 
Continuous Each prescribed medication was 
counted 
Medical 
records 
Doses frequency Continuous Total number of daily doses Medical 
records 
Presence of co-
morbidities 
Categorical - No 
- Yes 
Medical 
records 
Number of co-
morbidities 
Categorical - None 
- One 
- Two 
- Three or more 
Medical 
records 
BMI* Continuous BMI in Kg/m2 Medical 
records 
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Outcome measures 
LMQ Score Continuous  
Ordinal 
The overall score of the items or 
the score in categories: 
- (41 – 73): No burden at all 
- (74 – 106): Minimum burden 
- (107–139): Moderate burden 
- (140 – 172): High burden 
- (173 – 205): Extremely high 
burden 
LMQ tool 
LMQ VAS Score Continuous A score from 0 to 10 LMQ tool 
ARMS Score Continuous 
Dichotomous 
A score from 12 to 48 
- A score of 12: Adherent 
- Over 12: Non-adherent 
ARMS tool 
*Body Mass Index 
 
 
 
2.2.11.2. Normality Distribution 
Continuous variables of this research, including age, duration of diagnosis, number 
of prescribed medications, LMQ score, VAS score, ARMS score, and BMI, were tested for 
normality. The tests were performed using SPSS, and included Shapiro-Wilk test as well 
as Kolmogorov-Smirnov (K-S) tests (102). These tests were done to inform the selection 
of the statistical tests of medication-related burden assessment. 
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2.2.11.3 Statistical Tests  
Below is a description of the statistical tests used to answer the objectives of 
Phase 2 of the study. Tables 3 and 4 contain the details of the statistical tests used. 
2.2.11.3.1 Psychometric validation of the Arabic version of LMQ 
It is recommended to report the psychometric properties of the adapted tools 
among populations that differ from the populations in which they were developed (39, 
54, 57). The data produced from this research was used to measure: (1) the internal 
consistency reliability of the items in the Arabic version of the LMQ using Cronbach 
alpha and, (2) the construct validity of the Arabic version of the LMQ through 
correlations of the LMQ score with the VAS indicating global burden, clinical variables, 
and ARMS score representing adherence to medications. 
(1) Internal consistency reliability 
The internal consistency reliability (measured by Cronbach alpha) is a measure of 
reliability to assess if the scale’s items are measuring the underlying dimension or theme 
(103). This test was used to determine the internal consistency of each of the eight 
dimensions of the LMQ (Arabic version). 
(2) Construct validity 
Construct validity gives an insight about the ability of the instrument to measure 
the constructs it is supposed to measure, and it is preferred when there is no gold 
standard criterion available for the test of interest (48). As medication burden is assumed 
to be affected by treatment regimen and its consequences, the adapted LMQ’s construct 
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validity was tested using associations of the LMQ score with the ARMS score, prescribed 
medications and regimen, and each of the afore-mentioned clinical variables.  
 
Table 3. Summary of the statistical tests used to validate the Arabic version of the LMQ  
Category  
 
Variable measurement’s 
type 
Comparison 
 
Statistical test 
 
 Internal 
consistency 
Continuous 8 dimensions Cronbach Alpha 
Construct 
validity 
Continuous  
Ordinal 
Correlation of LMQ scores 
with adherence score/ VAS: 
global burden/ Specific 
dimensions 
Spearman’s 
correlation 
 
2.2.11.3.2 Assessment of medication-related burden 
1. Description of the sample: Descriptions and comparisons using frequencies and 
percentages were used to describe all the variables of the sample, and to express the 
perceived medication-related burden among the patients. (Table 4) 
2. Inferential statistics (univariate analysis) were also used to determine and 
compare the medication-related burden scores across different demographic and clinical 
characteristics. (Table 4) 
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2.2.11.3.3 Association between medication-related burden and self-reported 
medication adherence 
In order to demonstrate the relationship between the perceived medication-
related burden and adherence to medication therapy, correlation analyses were applied 
(104). As reported in the literature, perceived medication-related burden was assumed 
to be correlated with medication adherence (25, 60). Given the cyclic nature of perceived 
burden (60), the direction of this association was not hypothesized in this study. In order 
to further explain the score of the medication burden after accounting for the measured 
variables altogether, regression analysis was used. (Table 4) 
Table 4. Summar 
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y of the Statistical Tests Used to Assess Medication Burden and Associate it with Adherence 
Statistical 
purpose 
Variables/ measurement 
type 
Comparison Statistical tests 
Description  Continuous/ordinal  Descriptions of the study 
sample 
Frequencies 
and 
percentages 
Differences Dependent variable: LMQ 
score, ARMS score, and VAS 
score: continuous variables 
Difference of the 
distributions of medication 
burden, and adherence 
scores among the 
categories of patients 
Mann-Whitney 
and Kruskal-
Wallis  
Associations Continuous/ordinal Global scores of burden 
and adherence 
Spearman 
correlation co-
efficient 
Predictions Burden score as dependent 
variable: continuous 
More than one 
independent variables to 
explain the dependent 
variable 
Multiple 
regression 
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CHAPTER 3: RESULTS 
3.1 Phase 1: Translation and Cultural Adaptation of LMQ into the Arabic Context 
3.1.1 Translation and Cultural Adaptation of LMQ 
3.1.1.1 Title and Instructions 
The instrument’s title and the instructions were translated with no need for 
changes. Questions about demographics, which were at the end of the original LMQ, were 
moved to the first page to avoid missing important demographic data. The question about 
the ethnic group of the respondent was replaced by a question about nationality. The 
research team felt that nationality rather than ethnicity categorizes participants within a 
mostly similar ethnic group. 
3.1.1.2 Items of LMQ 
The 41 items contained in the instrument were evaluated carefully by the study 
investigators at the semantic, conceptual, and cultural levels. In this respect, some words 
were changed to retain the intended meaning and direction of the statement, and to suit 
the Arabic context (Table 5). 
An example of re-wording to reflect the Arabic context is as follows; within the 
items that contained the phrase “my doctor(s)”; we kept it as “doctor” since in Arabic 
mentioning both the plural and singular forms of the word would be lengthy and 
unnecessary to the sentence. In the Arabic Language, this translates to any number of 
doctors the patient is dealing with. 
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The backward translation review revealed no major issues in the translation. Only 
a few statements were rearranged to be easier and closer to the Arabic respondents’ 
understanding, while maintaining the intended meaning of the original statements. 
Details of the issues raised were reported to and discussed with the LMQ developers. 
Issues arising during the process of translation and cultural adaptation are summarized in 
Table 5. 
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Table 5. Major Issues Resolved in the Translation and Cultural Adaptation of the LMQ into Arabic 
No. Statement Translation issue Action 
4 “I am comfortable 
with the times I should 
take my medicines” 
When back-translated into 
English, the term 
“comfortable” became 
“relieved” which would change 
the meaning and the direction 
of the item. 
The word “comfortable” was 
translated into a word in Arabic 
that means “accept”. 
11 “I can vary the dose of 
the medicines I take” 
Literal translation may change 
the direction of the item and 
may give the meaning that the 
patient will change the dose 
regardless of the need. 
It was translated to express the 
confidence that respondent 
would have to tailor the dose as 
per their needs, which is the 
intended meaning of the item. 
17 “I am concerned that 
my medicines interact 
with alcohol” 
Cultural adaptation were 
performed to ensure 
acceptance of the respondents 
to answer such an item since 
alcohol consumption, while not 
uncommon, is not a norm in 
the Arabic culture. 
This was translated into Arabic 
in what means “I am concerned 
that my medicines interact with 
my nutritional habits (other 
foods, alcohol drinks)”. 
41 “My life revolves 
around using my 
medicines” 
If translated literally, it would 
be hard to 
understand and would deliver a 
different meaning and 
direction of the item. 
This item was translated into a 
sentence that means using 
medicines takes a major part of 
the life of the patient. 
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3.1.2 The Visual Analogue Scale 
A decision was made, through discussions among the research investigators, to 
change the scale to one with discrete, graduation between 0 (no burden at all) and 10 
(extremely burdensome) (Figure 2). This proposed change was communicated to (and 
approved by) the original instrument developers. The rationale for adding the discrete 
scores to the VAS was to help in providing a global self-assessment of the burden of 
medicine use and to allow measuring associations with the overall LMQ score and with 
each of its domains.  
 
 
Figure 2. Visual analogue scale representing global burden 
 
 
3.1.3 Cognitive Debriefing 
The characteristics of the individuals who participated in the cognitive debriefing 
interviews are summarized in Table 6. The interviews conducted revealed an overall good 
understanding of most of the questionnaire’s statements and their Arabic translation. 
Almost all of the interviewed individuals commented on the length of the questionnaire 
(41 items) and the presence of some items that cluster around similar meaning. For 
example, item 3 “I am satisfied with the effectiveness of my medicines”, and item 25 “My 
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medicines live up to my expectations” were, to some respondents, measuring the 
effectiveness of their medications. However, no changes were suggested regarding these 
items, because these closely-related questions have subtle differences between them. 
Respondents’ suggestions and comments regarding not only the Arabic, but also the 
original version were reported to the LMQ developers in details. 
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Table 6. Characteristics of Cognitive Debriefing Participants 
Participant Gender Nationality Age Occupation Interview 
place 
Interview 
duration 
P1 Female Syrian 26 Physical 
therapist 
Home 60 min 
P2 Female Qatari 35 Red crescent 
volunteer 
Coffee shop 50 min 
P3 Male Lebanese 57 Manager Participant’s 
office 
60 min 
P4 Female Syrian 23 University 
student 
Researcher’s 
office 
75 min 
P5 Female Libyan 28 University 
student 
Researcher’s 
office 
45 min 
P6 Male Qatari 58 Real estate 
expert 
Participant’s 
office 
40 min 
P7 Male Egyptian 45 Laborer Construction 
work site 
45 min 
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3.2 Phase 2: Measurement of Medication-Related Burden among Patients with Non-
Communicable Diseases 
Of the 500 eligible patients approached in the four heath centers, 307 were 
consented to participate in the study. After excluding forms with incomplete, or invalid 
data (i.e. the participant responded to only one questionnaire, or responded with neutral 
to all the items of the LMQ), a total of 293 patients were included in the analysis. The 
responses of these patients, in Arabic or English, were used to answer the remaining 
objectives of the research (LMQ-AR validation, medication-related burden assessment, 
and relationship between medication-related burden and adherence). 
3.2.1 Validation of the Arabic Version of the LMQ  
A subset of the patients who participated in the study completed the Arabic 
versions of the LMQ and ARMS (n = 138), during their regular visits to NCD clinics in Qatar. 
The median (IQR) age of this subset was 55.0 (16.0) years. Patients were mainly male 
(63.8%), non-Qatari Arabs (60.9%), married (92.8%), and educated (50% with university 
degree or higher). The median (IQR) duration of DM diagnosis was 10.0 (10.0) years, while 
the median (IQR) number of prescribed medications was 5.0 (3.0). Most of the patients 
(65.2%) had two or more co-morbidities (Table 7).    
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Table 7. Description of the Patients Who Responded to the LMQ Arabic Version (N =138) 
Variable Median (IQR) Frequency (%) 
Age  55.0 (16.0)  
Gender   
Male  88 (63.8) 
 Female  50 (36.2) 
Country of origin/ ethnicity   
Qatar  37 (26.8) 
Arab countries (excluding Qatar)  84 (60.9) 
Indian subcontinent  14 (10.1) 
Others  3 (2.2) 
Education Level   
Less than primary school  3 (2.2) 
Primary or middle school  29 (21.0) 
Secondary school  28 (20.3) 
Technical college  9 (6.5) 
University degree  61 (44.2) 
Postgraduate degree  8 (5.8) 
Marital status   
Married  128 (92.8) 
Single  4 (2.9) 
Divorcee  3 (2.2) 
Widowed  3 (2.2) 
Duration of DM diagnosis  10.0 (10.0)  
Number of prescribed medications 5.0 (3.0)  
Number of co-morbidities   
None  10 (7.2) 
One  38 (27.5) 
Two  54 (39.1) 
Three or more  36 (26.1) 
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The completion rate for the whole items in the questionnaire was 87%. The LMQ 
score was the sum of the response choices’ scores to all the 41 items, and ranged from 
41 to 205. All of the items were correlated with the overall score (rs ranged from 0.123 to 
0.685).   
3.2.1.1 Internal Consistency Reliability 
The Cronbach’s α coefficient of each of the eight domains (themes) of the LMQ-
AR, showed accepted to good internal consistency reliability (range 0.583 to 0.808). 
Tables 8 and 9 illustrate the internal consistency reliability and item analysis of the eight 
LMQ domains.  
 
Table 8. Internal Consistency Reliability of the LMQ Arabic Version 
Theme/Domain No. of 
items 
Cronbach’s 
α  
Relationships with healthcare providers 5 0.674 
Practical difficulties in using medicines 7 0.588 
Cost-related burden 3 0.704 
Side effects of medicines 4 0.781 
Effectiveness of medicines 6 0.616 
Attitudes/ concerns about using medicines 7 0.760 
Impact/ Interference to day-to-day life 6 0.808 
Control/ Autonomy of varying the regimen 3 0.583 
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Table 9. Item Analysis of the LMQ Arabic Version 
No. Items Median  
(IQR) 
Item-total 
correlation 
co-efficient 
Cronbach’s 
α if item is 
deleted 
Theme 1: Relationships with healthcare providers  
7 I trust the judgement of my doctor(s) in 
choosing medicines for me.   
2.0 (1.0) 0.083 0.748 
14 My doctor(s) listen to my opinions about my 
medicines. 
2.0 (2.0) 0.528 0.572 
20 My doctor(s) takes my concerns about side 
effects seriously. 
2.0 (2.0) 0.638 0.512 
24 I get enough information about my medicines 
from my doctor(s). 
2.0 (1.0) 0.498 0.589 
34 The health professionals providing my care 
know enough about me and my medicines 
2.0 (1.0) 0.419 0.629 
Theme 2: Practical difficulties in using medicines 
1  I find getting my prescriptions from the doctor 
difficult* 
2.0 (1.0) 0.400 0.516 
2 I find getting my medicines from the pharmacist 
difficult*  
2.0 (1.0) 0.437 0.500 
4 I am comfortable with the times I should take 
my medicines 
2.0 (1.0) 0.232 0.580 
10 I am concerned that I may forget to take my 
medicines* 
4.0 (2.0) 0.389 0.519 
23 I have to put a lot of planning and thought into 
taking my medicines* 
2.0 (2.0) 0.471 0.487 
27 It is easy to keep to my medicines routine 2.0 (0.0) -0.042 0.655 
29 I find using my medicines difficult* 2.0 (2.0) 0.286 0.557 
Theme 3: Cost-related burden 
5 I worry about paying for my medicines* 2.0 (3.0) 0.416 0.736 
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31 I sometimes have to choose between buying 
basic essentials or medicines* 
2.0 (2.0) 0.576 0.532 
33 I have to pay more than I can afford for my 
medicines* 
2.0 (3.0) 0.559 0.542 
Theme 4: Side effects of medicines 
21 The side effects I get are sometimes worse than 
the problem for which I take medicines* 
3.0 (2.0) 0.627 0.707 
22 The side effects I get from my medicines 
interfere with my day-to-day life (e.g. work, 
housework, sleep)* 
4.0 (2.0) 0.566 0.738 
30 The side effects I get from my medicines are 
bothersome* 
2.0 (2.0) 0.646 0.698 
38 The side effects I get from my medicines 
adversely affect my well-being* 
2.0 (2.0) 0.511 0.766 
Theme 5: Effectiveness of medicines 
3  I am satisfied with the effectiveness of   my 
medicines 
2.0 (1.0) 0.260 0.564 
15 My medicines prevent my condition getting 
worse 
2.0 (1.0) 0.357 0.515 
25 My medicines live up to my expectations 2.0 (0.0) 0.380 0.512 
32 My medicines allow me to live my life as I want 
to 
2.0 (1.0) 0.141 0.627 
39 My medicines are working 2.0 (1.0) 0.414 0.505 
40 The side effects are worth it for the benefits I 
get from my medicines 
2.0 (1.0) 0.472 0.480 
Theme 6: Attitudes/Concerns about using medicines 
6 I worry that I have to take several medicines at 
the same time* 
2.0 (2.0) 0.518 0.722 
8 I would like more say in the brands of medicines 
I use* 
2.0 (1.0) 0.337 0.757 
9 I feel I need more information about my 
medicines* 
4.0 (2.0) 0.452 0.737 
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12 I am concerned about possible damaging long 
term effects of taking medicines* 
4.0 (3.0) 0.524 0.721 
16 I am concerned that I am too reliant on my 
medicines* 
4.0 (2.0) 0.473 0.732 
17 I am concerned that my medicines interact with 
my nutritional habits (other foods - alcohol 
drinks)* 
2.0 (2.0) 0.511 0.724 
18 I worry that my medicines may interact with 
each other* 
3.0 (2.0) 0.524 0.721 
Theme 7: Impact/Interference to day-to-day life 
19 My medicines interfere with my social or leisure 
activities* 
2.0 (2.0) 0.691 0.747 
28 Taking medicines affects my driving* 2.0 (1.0) 0.555 0.781 
35 My medicines interfere with my social 
relationships* 
2.0 (4.0) 0.665 0.758 
36 Taking medicines causes me problems with daily 
tasks (such as work, housework, hobbies) * 
2.0 (1.0) 0.651 0.758 
37 My medicines interfere with my sexual life* 2.0 (1.0) 0.439 0.805 
41 My life revolves around using my medicines* 4.0 (2.0) 0.420 0.811 
Theme 8: Control/ autonomy of varying regimen 
11 I can vary the dose of the medicines I take 4.0 (2.0) 0.442 0.402 
13 I can choose whether or not to take my 
medicines 
4.0 (2.0) 0.347 0.545 
26 I can vary the times I take my medicines 4.0 (2.0) 0.392 0.482 
*Item was reverse coded 
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3.2.1.2 Construct Validity 
The results showed a significant moderate correlation between the overall LMQ 
score and ARMS score (rs=0.400). Similarly, there was a significant moderate correlation 
between the LMQ score and the global burden; VAS (rs=0.335). There were also significant 
associations between the scores of the domains (themes) of the LMQ and overall LMQ 
score, adherence score (ARMS), and global burden (VAS). Tables 10 and 11 illustrate these 
correlations. 
 
Table 10. LMQ-AR Correlations with Global Burden and Adherence Scores 
Spearman’s 
rho 
 LMQ N P value 
VAS: Global burden 0.400 119 <0.0001 
ARMS 0.335 120 <0.0001 
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Table 11. Correlations of the LMQ Domains with the Scores of LMQ, Adherence, and VAS: Global 
Burden (N = 138) 
Spearman’s 
rho 
LMQ domains LMQ 
Score 
VAS: global 
burden 
ARMS 
Score 
Relationships with healthcare providers 0.544 0.172 0.099 
P value <0.0005 0.05 0.628 
Practical difficulties in using medicines 0.727 0.287 0.303 
P value <0.0005 0.001 <0.0005 
Cost-related burden 0.536 0.145 0.337 
P value <0.0005 0.095 <0.0005 
Side effects of medicines 0.821 0.464 0.279 
P value < 0.0005 < 0.0005 0.001 
Effectiveness of medicines 0.521 0.218 0.725 
P value <0.0005 0.012 <0.0005 
Attitudes/Concerns about using 
medicines 
0.756 0.357 0.388 
P value <0.0005 <0.0005 0.002 
Impact 0.806 0.382 0.271 
P value <0.0005 <0.0005 0.002 
Control/Autonomy of varying regimen -  0.331 - 0.225 - 0.268 
P value < 0.0005 0.009 <0.0005 
 
 
3.2.2 Description of the Overall Sample 
Tables 12 and 13 contain the sociodemographic, clinical and other characteristics 
of the study participants. Most of the patients were young to middle age adults (78.4%), 
male (71%), non-Qataris (non-Qatari Arabs 41.6%), married (94.9%), educated (54.3% 
with university degree or higher), and employed (70.4%). The majority of the patients 
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(66.6%) reported that they were not following any lifestyle changes recommended by 
their healthcare providers. Smoking history (cigarette and shisha) revealed that the 
majority of the study cohort was never smoker.  
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Table 12. Sociodemographic Characteristics of the Patients who Participated in the Study (N = 293) 
Variable Frequency (%) 
Age (years)  
Up to 65 256 (87.4) 
Above 65 37 (12.6) 
Gender  
Male 208 (71.0) 
Female 85 (29.0) 
Country of origin/ ethnicity  
Qatar 41 (14.0) 
Arab countries (excluding Qatar)* 122 (41.6) 
Indian subcontinent** 107 (36.5) 
Philippines 14 (4.8) 
Others*** 9 (3.1) 
Education Level  
Less than primary school 3 (1.0) 
Primary or middle school 47 (16.0) 
Secondary school 52 (17.7) 
Technical college 32 (10.9) 
University degree 145 (49.5) 
Postgraduate degree 14 (4.8) 
Marital status  
Married 278 (94.9) 
Single 7 (2.4) 
Divorcee 5 (1.7) 
Widowed 3 (1.0) 
Lifestyle changes  
None 184 (62.8) 
Exercise 103 (35.2) 
Exercise & healthy diet 6 (2) 
Cigarette smoking  
Current smoker 32 (10.9) 
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Former smoker 42 (14.3) 
Never smoker 219 (74.7) 
Shisha smoking  
Current daily smoker 8 (2.7) 
Current social smoker 11 (3.8) 
Former smoker 16 (5.5) 
Never smoker 258 (88.1) 
Employment  
Employed 205 (70.4)**** 
Unemployed 68 (23.4) **** 
Retired 17 (5.8) **** 
Full-time student 1 (0.3) **** 
*Arabs countries include: Egypt, Jordan, Lebanon, Palestine, Sudan, Syria, Yemen, Iraq, Tunisia, 
and Morocco. 
**Indian subcontinent include: India, Pakistan, Sri Lanka, and Bangladesh. 
***Others include: Eretria, Hungary, Iran, Germany, Canada, Kenya, Brazil, and Britain 
****Percentages total may not be 100% due to some missing responses. 
 
 
All of the participants had DM with or without other comorbidities. The median 
(IQR) duration of DM diagnosis was 8.0 (8.0) years, with majority (66.6%) diagnosed from 
6 months to 10 years ago. Most of the patients (90.1%) had comorbidities, with 77.1% 
having up to three comorbidities. The most commonly reported comorbidities were; 
hypertension (55.3%), dyslipidemia (55.3%), and obesity (48.1%). Patients were 
prescribed with median (IQR) of 5.0 (3.0) medications, and 6.0 (3.0) daily doses. In 
addition, approximately 29% of the patients were prescribed more than five medications. 
Nearly 70% of the patients reported receiving help with their medicines. The diabetes 
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control status of the patients was determined using the most recently available HbA1c 
value in the medical records. The median (IQR) HbA1c value was 7.80% (2.3), and 66.2% 
of the patients had uncontrolled DM (HbA1c greater than 7%). In addition, the median 
(IQR) BMI of the study participants was 29.98 (6.68) kg/m2. 
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Table 13. Clinical Characteristics of the Study Participants (N = 293) 
Variable Median (IQR) Frequency (%) 
Duration of DM diagnosis 8.0 (8.0)  
6 months to 10 years  167 (66.5)* 
More than 10 years  84 (33.5) * 
Presence of co-morbidities  264 (90.1) 
Number of co-morbidities   
One  93 (31.7) 
Two  104 (35.5) 
Three or more  67 (22.9) 
Hypertension  162 (55.3) 
Dyslipidemia  162 (55.3) 
Vitamin D deficiency  18 (6.1) 
Thyroid dysfunction  10 (3.4) 
Obesity  141 (48.1) 
Asthma  6 (2) 
Others*  19 (6.5) 
Number of prescribed medications 5.0 (3.0)  
Up to 5 medications daily  208 (71) 
More than 5 medications daily  85 (29) 
Medication type   
Tablet/ capsules  211 (72) 
Any other type  82 (28) 
Help with medicines  88 (30.4)* 
HbA1c  7.80% (2.3)  
DM control status   
Controlled  85 (29)* 
Uncontrolled  194 (66.2)* 
BMI** (Kg/m2) 29.98 (6.68)  
*Percentages total may not be 100% due to some missing responses. 
**Body Mass Index 
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3.2.3 Medication-Related Burden Assessment  
3.2.3.1 Overall Perceived Medication-Related Burden 
Perceived medication-related burden was measured among the patients using the 
LMQ. The overall LMQ score was the sum of the scores of all the 41 items in the 
questionnaire, and ranged from 41 to 205, with higher scores indicating higher burden. 
The questionnaire also contained a VAS, through which respondents provided a global 
assessment of the overall burden they experience (0 to 10 points, with higher scores 
representing higher perceived burden).  The median (IQR) LMQ score and VAS score were 
95.00 (22) and 3.00 (4), respectively.  The findings showed that the majority of the 
patients suffer from minimum (66.6%) to moderate (24.1%) degrees of burden (Table 14). 
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Table 14. Perceived Medication-Related Burden Measured Using LMQ in Patients Attending NCD 
Clinics in Qatar (N = 293) 
Variable Range Mean (SD) Median 
(IQR) 
Frequency 
(%) 
LMQ overall score* (41–205) 97.5 (18.6) 95.0 (22)  
No burden at all (41–73)   18 (7.1) 
Minimum burden (74 –106)   169 (66.8) 
Moderate degree of burden (107–139)   61 (24.1) 
High burden (140–172)   5 (2) 
Extremely high burden (173–205)   - 
Theme 1: Relationships with healthcare  
professionals about medicines 
(5–25) 9.74 (3.12) 9.0 (4.0)  
Theme2: Practical difficulties (7–35) 15.19  (4.0) 15 (5.0)  
Theme 3: Cost-related burden (3–15) 6.75  (2.80) 6.0 (4.0)  
Theme 4: Side effects of prescribed 
Medications 
(4 – 20) 9.65  (3.72) 8.0 (5.0)  
Theme 5: Effectiveness of medicines (6 – 30) 11.36 (2.9) 12.0 (3.0)  
Theme 6: Attitudes/concerns about 
medicines use 
(7 – 35) 20.35 (5.3) 20.0 (9.0)  
Theme 7: Impact/Interference to day 
to-day life 
(6 – 30) 14.31 (4.4) 13.0 (6.0)  
Theme 8: Control/ Autonomy to vary 
Regimen 
(3 – 15) 10.17 (2.6) 10.0 (4.0)  
VAS: global burden (0 – 10) 3.17 (2.5) 3.0 (4)  
*Total of LMQ with complete responses is 253 due to some missing responses 
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3.2.3.2 Perceived Medication-Related Burden by Domains and Items 
Items measuring the themes (domains) of relationships with health care providers 
showed that 89.4% of the patients trusted the judgment of their physicians, 76.4% of 
them agreed that their physicians listen to their opinions about their medicines, 78.9% 
agreed that physicians take their concerns about side effects seriously, 78.5% get enough 
information from their physicians, and 83.6% agreed that the healthcare providers know 
enough about their conditions and medications (Table 15). 
 
Table 15. LMQ - Theme 1: Relationships with Healthcare Providers (N=293) 
Statement Strongly 
agree 
Agree Neutral Disagree Strongly 
disagree 
 Frequency (%)* 
7. I trust the judgement of my 
doctor(s) in choosing medicines 
for me  
139 (47.4) 123 (42) 13 (4.4) 11 (3.8) 6 (2) 
14. My doctor(s) listen to my 
opinions about my medicines 
93 (31.7) 131 (44.7) 22 (7.5) 33 (11.3) 13 (4.4) 
20. My doctor(s) takes my 
concerns about side effects 
seriously 
89 (30.4) 142 (48.5) 28 (9.6) 23 (7.8) 11 (3.8) 
24. I get enough information 
about my medicines from my 
doctor(s)  
82 (28) 148 (50.5) 22 (7.5) 31 (10.6) 8 (2.7) 
34. The health professionals 
providing my care know enough 
about me and my medicines 
104 (35.5) 141 (48.1) 28 (9.6) 15 (5.1) 3 (1) 
**Percentages total may not be 100% due to some missing responses. 
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Items evaluating practical difficulties in the experience of using medicines 
indicated that the majority of the patients did not find difficulties in getting prescribed 
medications from the physician (88.4%), or the pharmacist (84.9%), or to keep their 
medicines’ routines (82.2%). The participants were mostly comfortable with the times of 
taking their medicines (91.8%),  did not have to put a lot of planning in taking medicines 
(57.3%), with a substantial proportion of the respondents concerned about forgetting 
their medicines (41.3%) (Table 16). 
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Table 16. LMQ - Theme 2:  Practical Difficulties in Using Medicines (N=293) 
Statement Strongly 
agree 
Agree Neutral Disagree Strongly 
disagree 
 Frequency (%)* 
1. I find getting my 
prescriptions from the doctor 
difficult 
14 (4.8) 14 (4.8) 6 (2) 145 
(49.5) 
114 (38.9) 
2. I find getting my medicines 
from the pharmacist difficult 
12 (4.1) 21 (7.2) 11 (3.8) 140 
(47.9) 
108 (37) 
4. I am comfortable with the 
times I should take my 
medicines 
111 (37.9) 158 (53.9) 5 (1.7) 10 (3.4) 8 (2.7) 
10. I am concerned that I may 
forget to take my medicines 
26 (8.9) 95 (32.4) 44 (15) 99 (33.8) 29 (9.9) 
23. I have to put a lot of 
planning and thought into 
taking my medicines 
14 (4.8) 60 (20.5) 48 
(16.4) 
129 (44) 39 (13.3) 
27. It is easy to keep to my 
medicines routine 
59 (20.1) 182 (62.1) 25 (8.5) 21 (7.2) 5 (1.7) 
29. I find using my medicines 
difficult 
11 (3.8) 25 (8.5) 17 (5.8) 140 
(47.9) 
99 (33.9) 
*Percentages total may not be 100% due to some missing responses. 
 
 
The theme underlying cost-related burden showed that the majority of patients did not 
worry about paying for medicines (61.7%), did not have to choose between buying 
essentials or medicines (70.2%), and did not agree that medicines’ cost exceeded what 
they could afford (61.8%). (Table 17) 
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Table 17. LMQ - Theme 3: Cost-Related Burden (N=293) 
Statement Strongly 
agree 
Agree Neutral Disagree Strongly 
disagree 
 Frequency (%)* 
5. I worry about paying for my 
medicines. 
22 (7.6) 40 (13.8) 49 (16.9) 90 (31) 89 (30.7) 
31. I sometimes have to choose 
between buying basic 
essentials or medicines. 
11 (3.8) 36 (12.3) 40 (13.7) 99 (33.9) 106 (36.3) 
33. I have to pay more than I can 
afford for my medicines. 
11 (3.8) 63 (21.5) 38 (13) 99 (33.8) 82 (28) 
*Percentages total may not be 100% due to some missing responses. 
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The domain measuring burden related to side effects showed that a considerable 
proportion of patients were facing side effects: worse than the condition (24.6%), 
interfering with their daily lives (19.2%), bothersome (18.5%), or adversely affecting their 
well-being (24.4%) (Table 18). 
 
Table 18. LMQ-Theme 4: Side Effects of Medicines (N=293) 
Statement  Strongly 
agree 
Agree Neutral Disagree Strongly 
disagree 
 Frequency (%)* 
21. The side effects I get are 
sometimes worse than the 
problem for which I take 
medicines. 
22 (7.6) 49 (17) 37 (12.8) 134 (46.4) 47 (16.3) 
22. The side effects I get from 
my medicines interfere with my 
day-to-day life (e.g. work, 
housework, sleep). 
19 (6.5) 37 (12.7) 41 (14.1) 138 (48.4) 56 (19.2) 
30. The side effects I get from 
my medicines are bothersome. 
14 (4.8) 40 (13.7) 41 (14.1) 127 (43.6) 69 (32.7) 
38. The side effects I get from 
my medicines adversely affect 
my well-being. 
13 (4.5) 58 (19.9) 32 (11) 117 (40.2) 71 (24.4) 
*Percentages total may not be 100% due to some missing responses. 
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Furthermore, items measuring the effectiveness of medicines indicated that most 
of the patients agreed that they were satisfied with their medicines (89.7%), their 
medicines were working (94.5%), lived up to their expectations (88.7%), prevented their 
condition from getting worse (86.5%), allowed them to live as they want (80.5%), and 
worth the side effects they were facing (80%) (Table 19). 
 
Table 19. LMQ - Theme 5: Effectiveness of prescribed medications (n=293) 
Statement  Strongly 
agree 
Agree Neutral Disagree Strongly 
disagree 
 Frequency (%)* 
3. I am satisfied with the 
effectiveness of my medicines. 
112 (38.5) 149 (51.2) 13 (4.5) 11 (3.8) 6 (2.1) 
15. My medicines prevent my 
condition getting worse. 
103 (35.5) 148 (51) 17 (5.9) 16 (5.5) 6 (2.1) 
25. My medicines live up to my 
expectations. 
80 (27.4) 179 (61.3) 15 (5.1) 15 (5.1) 3 (1) 
32. My medicines allow me to live 
my life as I want to. 
81 (27.6) 155 (52.9) 22 (7.5) 27 (9.2) 8 (2.7) 
39. My medicines are working. 104 (35.9) 170 (58.6) 10 (3.4) 4 (1.4) 2 (0.7) 
 40. The side effects are worth it 
for the benefits I get from my 
medicines. 
84 (29.1) 147 (50.9) 33 (11.4) 16 (5.5) 9 (3.1) 
*Percentages total may not be 100% due to some missing responses 
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Regarding concerns about using medicines, items responses showed that patients 
mostly did not worry about taking several medicines (53.9%), were concerned about 
possible damaging effects of the medicines on the long-term (56.6%), were concerned 
that they were reliant on their medicines (47.1%), and were not worried about interaction 
between medicines and diet (63.2%), or  between each other (59%). Furthermore, 46.8% 
of the patients did not prefer to have more say in the brands of medicines they use, and 
47.4% needed more information (Table 20). 
  
 77 
 
Table 20. LMQ - Theme 6: Concerns about Medicines Use (N=293) 
Statement  Strongly 
agree 
Agree Neutral Disagree Strongly 
disagree 
 Frequency (%)* 
6. I worry that I have to take 
several medicines at the same 
time. 
29 (10) 76 (26.1) 29 (10) 115 (39.5) 42 (14.4) 
8. I would like more say in the 
brands of medicines I use. 
21 (7.2) 57 (19.5) 76 (25.9) 101 (34.5) 36 (12.3) 
9. I feel I need more information 
about my medicines. 
51 (17.4) 88 (30) 37 (12.6) 96 (32.8) 21 (7.2) 
12. I am concerned about possible 
damaging long term effects of 
taking medicines. 
61 (20.8) 105 (35.8) 45 (15.4) 66 (22.5) 15 (5.1) 
16. I am concerned that I am too 
reliant on my medicines. 
41 (14) 97 (33.1) 59 (20.1) 75 (25.6) 20 (6.8) 
17. I am concerned that my 
medicines interact with my 
nutritional habits (other foods - 
alcohol drinks). 
27 (9.2) 55 (18.8) 25 (8.5) 113 (38.6) 72 (24.6) 
18. I worry that my medicines may 
interact with each other. 
33 (11.3) 59 (20.1) 27 (9.1) 121 (41.3) 52 (17.7) 
*Percentages total may not be 100% due to some missing responses. 
 
 
The theme assessing the impact of the medicines on day-to-day life, indicated that 
the patients noticeably disagreed that their medicines interfered with social activities 
(69.1%), social life (80%), daily tasks (77.9%), driving (76.1%), or with sexual life (70.2%). 
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They also indicated mostly their agreement that their lives revolved around using 
medicines (51.9%) (Table 21). 
 
Table 21. LMQ -Theme 7: Impact of Using Medicines on Daily Life (N=293) 
Statement  Strongly 
agree 
Agree Neutral Disagree Strongly 
disagree 
 Frequency (%)* 
 19. My medicines interfere with 
my social or leisure activities. 
17 (5.8) 44 (15.1) 29 (10) 142 (48.8) 59 (20.3) 
28. Taking medicines affects my 
driving. 
9 (3.1) 25 (8.7) 35 (12.2) 120 (41.7) 99 (34.4) 
35. My medicines interfere with 
my social relationships. 
11 (3.8) 23 (7.9) 24 (8.3) 168 (57.9) 64 (22.1) 
36. Taking medicines causes me 
problems with daily tasks (such as 
work, housework, hobbies). 
11 (3.8) 37 (12.8) 16 (5.5) 158 (54.5) 68 (23.4) 
37. My medicines interfere with 
my sexual life. 
15 (5.1) 27 (9.2) 45 (15.4) 110 (37.7) 95 (32.5) 
41. My life revolves around using 
my medicines 
57 (19.5) 95 (32.4) 79 (27) 47 (16) 12 (4.1) 
*Percentages total may not be 100% due to some missing responses. 
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Lastly, items measuring autonomy to vary regimen showed patients’ 
disagreement to their ability to vary the dose of their medicines (59.5%), choose whether 
or not to take medicines (73.7%), or to vary the times of taking medicines (48.4%) (Table 
22).  
 
Table 22. LMQ -Theme 8: Autonomy to Vary Regimen (N=293) 
Statement  Strongly 
agree 
Agree Neutral Disagree Strongly 
disagree 
 Frequency (%)* 
11. I can vary the dose of the 
medicines I take. 
27 (9.2) 70 (24) 21 (7.2) 133 (45.5) 41 (14) 
13. I can choose whether or not to 
take my medicines. 
11 (4) 54 (19.5) 8 (2.9) 150 (54.2) 54 (19.5) 
26. I can vary the times I take my 
medicines. 
22 (7.5) 111 (37.9) 16 (5.5) 117 (39.9) 25 (8.5) 
*Percentages total may not be 100% due to some missing responses. 
 
 
3.2.3.3 Open-Ended Question 
Only 14 patients responded to the open-ended question regarding their views 
about how medication-related burden affected their lives. Ten issues emerged from their 
comments. These issues are summarized in Table 23. 
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Table 23. Additional Issues Contributing to Medication Burden Identified by the Study Participants 
(N=14) 
No. Issues identified in the comment 
1 Travel time to utilize healthcare 
2 Side effects of the medicines 
3 Technical issues of medicines’ refill system 
4 Long waiting periods before seeing the physician 
5 Seeing different physician for each follow-up appointment 
6 Lack of information and instructions to live with their health conditions 
7 Worry about taking several medicines at the same time, and about side effects of 
medicines 
8 Worry about the long-term effects of the chronic condition on the body organs 
9 Lack of information regarding the side-effects of the medicines, and their effect on 
the body 
10 Feeling that follow-up appointments are not enough 
 
 
3.2.3.4 Self-Reported Adherence 
Adherence was measured using ARMS, and the results showed that 84% of the 
patients were non-adherent to their prescribed medications (Table 24). Table 25 contains 
the results of the responses to the individual ARMS items. 
 
Table 24. Self-Reported Adherence of Patients with Chronic Conditions Attending NCD Clinics in 
Qatar Measured By ARMS (N = 293) 
Variable Mean (SD) Median (IQR) Frequency (%) 
ARMS overall score 17.4 (4.8) 16.0 (7)  
Adherent   47 (16) 
Non-adherent   246 (84) 
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Table 25. Self-Reported Adherence of Patients Attending NCD Clinics in Qatar Measured By ARMS 
Items (N = 293) 
 
 
VariableItIefaweItem None of the 
time 
Some of 
the time 
Most of 
the time 
All of the 
time 
 Frequency (%) 
1.”How often do you forget to take your 
medicine?” 
169 (57.7) 118 (40.3) 5 (1.7) 1 (0.3) 
2. “How often do you decide not to take 
your medicine?” 
212 (72.4) 72 (24.6) 5 (1.7) 4 (1.4) 
3. “How often do you forget to get 
prescriptions filled?” 
218 (74.4) 57 (19.5) 16 (5.5) 2 (0.7) 
4. “How often do you run out of medicine?” 189 (64.5) 83 (28.3) 20 (6.8) 1 (0.3) 
5. “How often do you skip a dose of your 
medicine before you go to the doctor?” 
195 (66.6) 74 (25.3) 17 (5.8) 7 (2.4) 
6. “How often do you miss taking your 
medicine when you feel better?” 
199 (67.9) 75 (25.6) 11 (3.8) 8 (2.7) 
7. “How often do you miss taking your 
medicine when you feel sick?” 
219 (74.47) 56 (29.1) 13 (4.4) 5 (1.7) 
8. “How often do you miss taking your 
medicine when you are careless?” 
202 (68.9) 73 (24.9) 9 (3.1) 9 (3.1) 
9. “How often do you change the dose of 
your medicines to suit your needs (like 
when you take more or less pills than you’re 
supposed to)?” 
196 (66.9) 76 (25.9) 16 (5.5) 5 (1.7) 
10. “How often do you forget to take your 
medicine when you are supposed to take it 
more than once a day?” 
162 (55.3) 113 (38.6) 14 (4.8) 4 (1.4) 
11. “How often do you put off refilling your 
medicines because they cost too much 
money?” 
224 (76.5) 43 (14.7) 11 (3.8) 15 (5.1) 
12. “How often do you plan ahead and refill 
your medicines before they run out?” 
136 (46.4) 73 (24.9) 49 (16.7) 35 (11.9) 
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3.2.3.5 Influence of Patients’ Demographic and Clinical Characteristics on Medication 
Burden 
Mann-Whitney U and Kruskal-Wallis tests were used to determine the influence 
of sociodemographic and clinical characteristics of participants on perceived medication 
burden. Table 26 describes the details of the findings of these tests. 
Median LMQ score for Qataris was significantly higher, representing worse 
experience worse medication-related burden, than that for non-Qataris, (p = 0.011). 
Patients who had spouses showed significantly lower LMQ scores than patients who did 
not have spouses (p = 0.002).  
Statistically significant differences were also found between median scores of 
LMQ of different categories of employment status (p = 0.036). Subsequently, pairwise 
comparisons were performed using Dunn's (1964) procedure with a Bonferroni correction 
for multiple comparisons. This revealed statistically significant differences in median LMQ 
scores between the employed and non-employed patients, (p = 0.044).  
Furthermore, patients diagnosed with DM for more than 10 years showed 
statistically significantly higher median LMQ score than that of patients who had the 
diagnosis for less than 10 years (p = 0.007).  
According to VAS scores representing global burden, patients with uncontrolled 
DM reported significantly higher global burden than patients with controlled DM (p = 
0.018). Furthermore, median VAS score for patients diagnosed with DM for more than 10 
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years was significantly higher  than that for patients diagnosed with DM for less than 10 
years (p = 0.043).  
 
Table 26. The Influence of Sociodemographic and Clinical Characteristics on LMQ and VAS Scores 
among Patients Attending NCD Clinics in Qatar (N=293) 
Variable LMQ score VAS 
 Median (IQR) 
Gender   
Male 93.00 (20) 3.00 (4) 
Female 101.50 (34) 3.00 (5) 
P value 0.053 0.736 
Age    
Up to 65years 96 (19) 2.46 (4) 
Over 65 years 93 (34) 2.56 (3.5) 
P value 0.984 0.406 
Country of origin   
Qatari 103.00 (24) 
4.00 (5) 
Non-Qatari 94.00 (20) 
3.00 (4) 
P value 0.011 0.256 
Marital status   
Spouse 94.00 (21) 
3.000 (4) 
No spouse 
114.00 (24) 
2.000 (7) 
P value 0.002 0.394 
Education Level   
Less than primary school 103.00 0.00 
Primary or middle school 97.00 (25) 2.00 (5) 
Secondary school 97.00 (16) 3.00 (4) 
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Technical college 80.00 (29) 3.00 (4) 
University degree 93.00 (21) 3.00 (4) 
Postgraduate degree 106.00 (28) 3.50 (2.8) 
P value 0.157 0.354 
Comorbidities   
No 101.00 (25) 2.00 (3.8) 
Yes 95.00 (21) 3.00 (4.0) 
P value 0.537 0.723 
No of co morbidities   
None 101.00 (25) 2.00 (3.8) 
One 92.00 (22) 3.00 (3.8) 
Two 97.00 (22) 3.00 (5.0) 
Three or more 95.50 (20) 3.00 (4.0) 
P value 0.255 0.925 
DM diagnosis duration   
6 months to 10 years 93.00 (19) 3.00 (4.0) 
Over 10 years 100.00 (32) 3.25 (5.0) 
P value 0.007 0.043  
Prescribed medications   
Up to 5 daily medications 95.00 (23) 3.00 (4.0) 
Over 5 daily medications 96.00 (18) 2.75 (4.0) 
P value 0.324 
Medication type   
Tablet/ capsules 94.00 (19) 3.00 (4.0) 
Any other type 97.00 (26) 3.00 (4.0) 
P value 0.210 0.026 
Help with medicines   
No 96.00 (22) 3.00 (4.0) 
Yes 94.00 (20) 3.00 (3.0) 
P value 0.216 0.520 
DM Control status   
Controlled 94.50 (17) 2.00 (4.1) 
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Uncontrolled 96.00 (22) 3.00 (4.0) 
P value 0.458 0.018 
Cigarette Smoking   
Current smoker 100.00 (20) 3.00 (3.0) 
Former smoker 93.00 (20) 3.00 (4.0) 
Never smoker 96.00 (21) 3.00 (4.0) 
P value 0.628 0.627 
Shisha Smoking   
Current daily smoker 101.00 (6.0) 3.50 (7.0) 
Current social smoker 92.00 (38) 2.00 (4.0) 
Former smoker 92.00 (44) 3.50 (2.3) 
Never smoker 95.00 (22) 3.00 (4.0) 
P value 0.716 0.660 
Lifestyle changes   
None 96.00 (21) 3.00 (4) 
Exercise 94.50 (20) 3.00 (4) 
Exercise & healthy diet 77.00 1.50 
P value 0.720 0.751 
Employment   
Employed 93.00 (19) 3.00 (4) 
Non-employed 103.00 (33) 3.00 (4.9) 
Retired 95.00 (36) 3.00 (4) 
Full-time student 114.00 1.50 
P value 0.036 0.874 
 
3.2.3.6 Relationship between Medication Burden and Adherence 
A Spearman's rank-order correlation was used to assess the relationship between 
perceived burden (LMQ and VAS scores) and adherence to prescribed medications (ARMS 
score) among the study population. Preliminary analysis showed the relationship to be 
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monotonic, as assessed by visual inspection of a scatterplot (Figure 3). As shown in Table 
27, there was a moderate positive correlation between LMQ score and ARMS 
score, rs(251) = 0.317, p < 0.0005. This correlation implies that the more medication-
related burden, the lower adherence level. There was also a moderate positive 
correlation between the VAS scores and ARMS score, rs(284) = 0.325, p < 0.0005. This 
indicates also that the more perceived burden, the lower the adherence level. 
 
Figure 3. Relationship between the scores of LMQ and ARMS (n=293) 
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Table 27. Correlation between Medication-Related Burden (LMQ and VAS Scores), and 
Adherence (ARMS Score) 
 LMQ Score VAS: global burden 
 Spearmen’s rho (P value) 
ARMS Score 0.317 0.325 
P value <0.0005 <0.0005 
 
Spearman's rank-order correlations were also conducted to evaluate the 
relationship between each of the eight domains (themes) of LMQ and ARMS scores as 
well as VAS. Practical difficulties, cost, side effects, attitudes, and impact of using 
medicines, showed significant positive correlation with adherence score (p < 0.05). On 
the other hand, autonomy of varying regimen showed significant negative correlation 
with ARMS (p < 0.05). However, relationships with healthcare providers and effectiveness 
of medicines domains were not significantly associated with adherence. Regarding the 
VAS, which represents global burden, it showed statistically significant correlation with 
all of the domains, except the cost domain. Table 28 summarizes these correlations. 
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Table 28. Correlations of LMQ Domains with VAS and ARMS Scores 
LMQ domains LMQ Score VAS: global burden ARMS Score 
 Spearman’s rho 
Relationships with healthcare providers 0.680* 0.245* 0.099**** 
Practical Difficulties in using medicines 0.748* 0.292* 0.291* 
Cost- related burden 0.360* 0.078**** 0.226* 
Side effects of medicines 0.818* 0.370* 0.240* 
Effectiveness of medicines 0.585* 0.218* 0.081**** 
Attitudes/ concerns about medicines use 0.760* 0.370* 0.329* 
Impact on day-to-day life 0.838* 0.329* 0.248* 
Control/Autonomy of varying the regimen -0.177** -.161*** -0.214* 
*P <0.0005,**P = 0.005, ***P = 0.009, ****P > 0.005 
 
 
To further understand the effect of the ARMS score (adherence) on the LMQ score 
(medication-related burden), a simple linear regression was performed. Linearity was 
evaluated through visual inspection of the scatterplot between the two scores with 
superimposed regression line (Figure 3). There was homoscedasticity and normality of the 
residuals. Two participants were outliers with LMQ scores of 152 and 147. These were 
removed from the analysis due to not representing the target population. The prediction 
equation was: LMQ score = 74. 509 + 1.317*ARMS score. Average ARMS score 
significantly predicted LMQ score, F (1, 249) = 35.85, p < .0005, accounting for 12.6% of 
the variation in burden score with adjusted R2=0.122, a medium effect size according to 
Cohen (1988). An extra one score of ARMS representing non-adherence leads to 1.317 
increase in medication burden (95% CI, 0.884 to 1.751).  
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A stepwise multiple linear regression was conducted to determine if the addition 
of the other collected variables improve the explained variance and prediction of LMQ 
score. The multiple regression model significantly predicted LMQ score, F (5, 204) = 
13.212, p < .0005, adj. R2 = 0.226. The variables that added statistically significant changes 
to the prediction, p < .05 were ARMS score, DM diagnosis duration, marital status, 
employment status, and presence of hypertension (HTN). Regression coefficients and 
standard errors can be found in Table 29. 
 
Table 29. Coefficients and Standard Errors of Multiple Regression Analysis Predicting Medication 
Burden Score 
Variable B* SEB** Beta *** 
Intercept 98.113 4.361  
ARMS score 1.297 0.232 0.342**** 
Employment -7.526 2.452 -0.191**** 
DM diagnosis duration 7.697 2.410 0.203**** 
Marital status -13.578 5.180 0.161**** 
HTN -4.768 2.290 -0.131**** 
* B = unstandardized regression coefficient 
**SEB = standard error 
*** Beta = Standardized coefficient 
****P < 0.05 
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CHAPTER 4: DISCUSSION 
4.1 Phase 1: Translation and Cultural Adaptation of LMQ into the Arabic Context 
The development of the LMQ aimed to introduce an instrument that assesses the 
burden related to the use of medicines from a patient’s perspective (25).  This work 
emphasizes the view that medication intake is perceived differently by patients when 
compared to healthcare providers (105).  
While studies focusing on culturally adapting measures may vary in their 
methodologies, we committed to follow best practices provided by ISPOR to ensure 
credible outcomes. Current recommendations in the literature propose adopting already 
existing tools for use in different study environments and setting (54, 55, 57). However, 
achieving cultural equivalence of measurement tools in practice is important to enhance 
the comparability of results generated from the use of these tools in different cultures 
(55). The use of questionnaires among societies with different cultures should only be 
performed after generating data that supports the validity of these measures within the 
target environment (54).  
Different approaches had been used to conduct translation and cultural 
adaptation processes (39, 54, 106). For example, Santo et al. have adapted the Brazilian-
Portuguese version of a self-report measure for dry eye from the US English version. 
Within their nine-step approach in cultural adaptation, they performed the back-
translation on the final adapted version after it has been tested for comprehension. On 
the other hand, prior to conducting the translation of the French Treatment Burden 
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Questionnaire into English, Tran et al. characterized the concept which the tool of interest 
measures among the target population (English-speaking). This diversity is due to the 
enormous differences in languages, cultures, and settings where these studies have been 
conducted, in addition to the diversity of the types of the tools adapted. 
As the statements of the LMQ were derived from earlier qualitative investigations 
among patients diagnosed with chronic morbidities (25), they were found to be clear and 
easy to understand by participants of different backgrounds. Our study revealed no major 
challenges during the translation process. This may be due to the fact that guidelines were 
carefully followed in order to maintain the cultural equivalence besides the 
questionnaire’s intended meaning.  
Decisions regarding the addition, elimination, or re-wording items of instruments 
to maintain the cultural equivalence in questionnaire translation and validation processes 
have been described in the literature (39, 58). In the current study, several issues 
emerged; most notably was a question among the demographic information page where 
participants are asked about their ethnic group. A decision was made to replace the ethnic 
group with the nationality as a better identifier among the Arabic-speaking people. Also 
an item where respondents were asked about concerns related to interactions between 
alcohol and other medications raised some concerns related to culture sensitivities. We 
proposed changing or re-wording the question because, despite the fact that consuming 
alcohol is not uncommon, it is still considered socially unacceptable in the Arabic culture 
and therefore seemed out of place in its original format in the questionnaire. The point 
was that including alcohol consumption as the main focus within an item in the 
 92 
 
questionnaire seemed inappropriate. It was not totally deleted; but the item was 
paraphrased such that alcohol consumption remained within an item that covered other 
dietary items and their potential interactions with medications.  
Discussion was raised with the developers regarding the inclusion of a non-
graduated VAS which was added at the end of the LMQ. The investigators of this study 
proposed the use of VAS with scores ranging from 0 to 10; this was to help in the 
interpretation of the findings resulting from using this tool, a suggestion that was 
approved by the developers. 
The cognitive debriefing interviews were conducted to assess the comprehension 
and time burden of the questionnaire. The overall good level of comprehension of almost 
all the statements within the tool was predicted as the development of the LMQ was 
based on qualitative explorations of patients’ perspectives on medication-related issues. 
The respondents’ comments about the length of the questionnaire and the redundancy 
of some items could be explained by the fact that this tool was designed to identify almost 
all possible issues related to medicine intake. This is not unusual, where in previous 
studies criticism of the original instrument occurred and changes that could affect its 
central construct were proposed as a result of testing the tool in different populations 
(39, 54, 106).  
Most of the guidelines regarding translation and cultural adaptation of patient-
reported outcome measures recommend that the back translation is carried out by a 
native speaker of the original language who is also fluent in the target language. Finding 
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a person with such characteristics in our setting was difficult (English native speaker who 
is also fluent in Arabic). The back translation in our study was performed by a qualified bi-
lingual translator whose mother language was Arabic, and who was familiar with the 
western culture. While cultural adaptation was rigorous, and research usually use 
versions of scales emerging from such studies (79), further research was warranted to 
determine the psychometric properties of the produced Arabic version (LMQ-AR) among 
Arabic-speaking populations. Specifically, the construct validity and internal consistency 
reliability that needed to be measured.  
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4.2 Phase 2: Measurement of Medication-Related Burden among Patients with Non-
Communicable Diseases 
This study was the first to measure medication-related burden from the 
perspective of patients living with chronic health diseases, attending NCD clinics at PHCC 
in Qatar. As majority of the patients visiting NCD were suffering from diabetes, we 
deliberately investigated medication –related burden among patients with diabetes as 
the main NCD disease focus.  
The Living with Medicines Questionnaire was used to measure aspects of 
medication –related burden experienced by the NCD patients. Although almost all of the 
patients interviewed found this measure extremely relevant, the majority of them 
commented on the length of it. For this reason, 86.3% of the cohort of patients provided 
complete responses to all of the items of the LMQ and the remaining minority of patients 
provided comments in the open-ended question at the end of the questionnaire. This 
might be due to questionnaire filling fatigue experienced by the participants. 
Our cohort of patients resembled the population in Qatar (107), with the majority 
of them were males, and from different nationalities. As expected, and similar to previous 
studies (9, 79), most of our patients suffered several comorbidities, had been prescribed 
several medications, non-adherent with their therapy, with uncontrolled diabetes, and 
adopted  an inactive life style. 
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4.2.1 Validation of the Arabic Version of LMQ 
The data generated from this study allowed us to measure the psychometric 
properties of the LMQ-AR. To validate any PROM, data should be generated through a 
study that uses the scale of interest (39, 52, 54), and this was the case in our study (phase 
2). As the Arabic version of the LMQ was adapted from the original English tool, best 
practice requires the assessment of its construct validity and internal consistency among 
patients representing the new target population. 
The validation work of LMQ-AR utilized data generated from 138 Arabic-speaking 
patients with chronic conditions (mainly diabetes). As indicated by validation study of the 
original tool, the LMQ contained 8 themes (domains), with several items clustering under 
each of them. Our internal consistency results provided evidence supporting this 
clustering. As hypothesized, perceived medication-related burden was significantly 
associated with adherence to medications as well as to the VAS indicating global burden. 
This study is one of few studies that investigated these associations as independent of the 
context of the disease and its treatment (39). In the validation of the TBQ in English 
(another tool to measure treatment burden), Tran et al have also found significant 
association between perceived burden and self-reported adherence (39). These results 
were expected due to the presence of qualitative studies highlighting the relationship 
between perceived burden and adherence (45, 59, 60). Finally, our results provided 
evidence supporting the validity of the original tool (95). 
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4.2.2 Medication–Related Burden Assessment 
As the interest in conceptualizing and measuring medication-related burden is 
relatively new, there are currently only few studies to compare our results to. To our 
knowledge, this is one of the first studies to assess medication-related burden among 
patients with NCDs from the perspective of the patients as independent measure from 
the disease or medication context (79). Our study indicated that a considerable 
proportion of the patients (90%) were suffering from varying degrees of burden related 
to their medication and overall treatment. As expected, this burden was minimum to 
moderate, given the high quality services provided to NCD patients in Qatar at minimal 
cost, and in one clinical setting. Previous studies indicated that 44.6% of patients with 
diabetes were suffering from the consequences of treatment (namely, diabetes distress) 
(108). However, that findings were derived as part of quality of life measure, which was 
related to the characteristics of a specific condition (108). The results of the current study 
can best be compared to the results of a recent study conducted in Australia, which 
assessed overall treatment burden among patients with chronic conditions (79). Although 
in that study, Sav. et al used a different tool (TBQ), the main focus of their measurement 
was still close to that of our study. They have also found that, independently from the 
ailment itself, treatment burden affected considerable proportion of patients with 
chronic diseases. Similar to our study, they have further highlighted the effects of 
patients’ characteristics on the perceived burden (79). 
Moreover, patients of Qatari nationality, females, patients without spouses, 
unemployed patients, patients diagnosed with DM for more than 10 years, patients with 
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uncontrolled DM demonstrated significantly higher scores of medication burden, and 
those who are prescribed with medication types other than tablets or capsules. Cultural 
differences between Qatari nationals and non-Qatari residents could translate into 
different levels of perceiving burden resulting from therapy. As indicated in other studies, 
females tended to show higher levels of burden than males (16, 27). These findings also 
indicate that having someone to provide support, and having a job could reduce the 
burden perceived by the patient. Our results also highlights the importance of the 
controlled status of the chronic condition in living with less burden. As expected, living 
longer with the disease, or being prescribed with any other dosage form other than pills, 
could translate into suffering more with the treatment and its consequences. 
As pointed out, only few patients (n = 14) responded to the open-ended question 
that asks respondents to raise any issues related to medication intake. These respondents 
raised 10 issues, which they consider burdensome. Among the raised issues, only five 
were not covered in the LMQ. These are travel time to utilize treatment, waiting time, 
issues related to the refill system, having to meet different physician in each appointment, 
and lack of sufficient number of follow-up appointments. Those highlighted burdensome 
issues were discussed in other studies focusing on overall treatment burden (16, 27, 60).  
Adherence has been reported in literature to be a factor that can affect or be 
affected by the perceived burden (70). However, measuring this effect quantitatively is 
lacking. To the best of our knowledge, this is one of the first studies to measure adherence 
and investigate its association with burden. We have found significant positive association 
between the scores of medication burden and self-reported adherence. This finding 
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supports the qualitative studies suggesting lack of adherence among patients who suffer 
from medication burden (18, 27). In a study used to validate TBQ among patients with 
chronic conditions from many English-speaking countries, Tran et al. found higher 
perceived burden among patients with lower levels of adherence (39).  
The current study has also provided evidence regarding the correlation of LMQ 
domains with global burden (VAS), LMQ score, and adherence. Impact of using medicines 
and side effects showed the strongest correlation with LMQ score, followed by attitudes/ 
concerns about medicines. Whereas the domains; effectiveness of medicines, 
relationships with healthcare providers, cost-related burden, and control of varying the 
regimen, showed moderate to weak associations with LMQ score. This suggests the 
contribution of each domain to the overall perceived medication-related burden among 
the studied population. This implies that the “impact on daily life”, “side effects”, 
“concerns about medicines”, and “practicalities”, respectively, were the strongest 
contributors in perceived medication-related burden among patients receiving care in 
NCD clinics. On the other hand, the cost-related burden and the control of varying 
regimens showed the weakest correlation with the LMQ score, suggesting their minimal 
contribution to the perceived burden.  
Similarly, global burden represented by VAS was not significantly associated with 
cost-related burden. This can be explained by the affordable prices patients pay for their 
regular medications and follow up at PHCC in Qatar. Interestingly, autonomy with varying 
regimen was negatively associated with global burden as well as LMQ score. This means 
that less control is associated with less burden, and this contradicts the magnitude of 
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association between this domain and the total LMQ score (of the original version). 
However, this contradiction could be explained by culture differences between the 
population among whom the tool was developed, and those where the adapted tool was 
applied. For example, the concept of patients’ autonomy in making therapeutic decisions 
as one of the patients’ rights is applied and well understood in societies where the LMQ 
was developed. For this reason, more control of medication regimens is translated into 
less burden. On the other hand, in Arab countries there are still barriers to a well-
established system in which patients will be fully involved in the control of their 
treatments (109, 110). Subsequently, less control was associated with less burden in our 
setting. 
Moreover, adherence was associated with all themes of burden except the 
relationship with healthcare providers and effectiveness of medicines. This suggests that 
adherence in not related to these two aspects of medication burden. 
As adherence alone explained only 12% of medication-related burden, we have 
further incorporated all the possible confounding factors in regression model as an 
attempt to investigate the factors that can explain or predict the perceived medication 
burden. Regression results suggest that the mean medication burden for participants with 
diabetes alone for less than 10 years, without spouse, and not employed, will be 98.113 
(minimum burden) (standard error 4.361), out of possible score 205. The presence of 
hypertension surprisingly reduces the burden score by -4.768 (standard error 2.290). This 
could be due to the fact that an additional diagnosis of hypertension (one more NCD) 
could create more awareness of risk factors, and hence less perceived burden by the 
 100 
 
treatment. This finding contradicts the finding by Sav. et al who highlighted that having 
extra chronic condition would lead to increase treatment burden (79). Furthermore, the 
presence of spouse as well as having a job were associated with reduced medication 
burden score by 7.526, 13.578, respectively. This is expected, since the evidence from 
literature suggests that having familial support in the life of the patients with chronic 
disease (79), as well as a steady job reduces the perceived burden. Finally, exceeding 10 
years of living with the chronic condition (diabetes in our case) increased burden score by 
7.697 (standard error 2.410). Although one would assume that living more with the 
disease could mean learning more about it, getting used to its management, and hence 
feeling less burden; our results suggest that this was not the case in our sample. This could 
be explained by the possibility that the longer someone suffers a health condition and 
uses treatment for it, the more h/she experience multiple issues related to long-term 
adverse treatment effects.  
4.3 Limitations and Future Studies 
This study has several limitations that warrant mention to benefit future research. 
First, as a cross-sectional study, it meant that we could not capture all factors that might 
have affected medication-related burden over time. Longitudinal studies would be better 
capable to investigate the effect of those factors on perceived burden over time. Second, 
some of the variables (for example diagnosis duration, lifestyle changes) were obtained 
from the patients, and this could be subject to recall bias. Third, it is true that self-
reported adherence is still considered the most feasible, user-friendly, and simple way of 
adherence measurement(111), but combination of subjective and objective methods of 
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measuring adherence is recommended (112). The research team initially aimed to 
measure adherence using the ARMS tool as well as the formula of Proportion of Days 
Covered (PDC) (113). However, after piloting of the procedure of phase 2 of this research, 
calculation PDC was not feasible given the scarce data that was kept at the pharmacy. 
Fourth, this study was restricted to patients who were able to communicate in English or 
Arabic. Hence, results cannot be generalized to people coming from different cultures 
constituting a considerable proportion of the population in Qatar. In fact, perceived 
burden could be affected by factors related to the differences in beliefs about 
medications (60); and such differences can also be related to culture. Future studies 
investigating these factors are recommended.  
Fifth, although stratified or systematic sampling techniques would have been the 
most suitable for this study to produce generalizable results, but convenience sampling 
was utilized for two reasons: (1) limited access to three health centers as per ethical 
approval conditions, and (2) formulating a sampling frame of eligible patients was not 
feasible due to the nature of patients’ visits to the NCD clinics. Although our sample 
demographic information resembles those of the population in Qatar, it may not be 
representative of it due to the limitation of sampling technique. Moreover, in spite of the 
use of comparisons in analyses, the sample size calculation was for descriptive study. This 
is because the main focus of the study was to measure medication-related burden for the 
first time. However, we approached more patients than the estimated sample size to 
account for this issue. 
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Finally, regarding data collection, questionnaires were self- or interviewer- 
administered. This can be considered a limitation due to possible positive or social 
desirability in case of the interviewer based administration. Furthermore, the use of two 
methods, could compromise the reliability of the results obtained from the study 
instruments. However, during the interviews, the researcher made sure to restrict her 
role to objectively read the tools’ items in order to limit the influence on patient’s 
responses. 
Furthermore, as much as this study is important in highlighting the presence of 
medication-related burden as a possible barrier to achieve the maximum benefits of 
health care services provided to patients in Qatar, the critical role of the healthcare 
providers (e.g. pharmacists) in reducing medication-related was not investigated in this 
study. This, however, warrants further research specifically designed to investigate the 
role of healthcare practitioners in reducing medication-related burden. 
Finally, we have attempted to investigate the effect of confounding factors on the 
perceived medication burden. The results of this investigation could be considered 
preliminary, as the main focus of the study was not about investigating this effect, and 
the sample size was not calculated based on regression. For example, beliefs about 
medications, which play a considerable role in perceived burden, was not assessed in this 
study. Future studies (qualitative and quantitative) with the aim of understanding the 
characteristics of the patients struggling with burden are needed.  
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4.4 Conclusion 
This research has produced an Arabic version of the Living with Medicines 
Questionnaire (LMQ-AR), adapted it into the Arabic context, and demonstrated the 
psychometric properties of it. The study further used this adapted tool in measuring 
medication-related burden among patients with chronic diseases attending primary care 
clinics in Qatar. A considerable proportion of those patients suffer from medication 
burden, which could be affected by many factors including adherence to drug therapy, 
duration of the diagnosis, control of the disease, being employed, or receiving support 
from family. Our study findings suggest that healthcare professionals should be aware of 
the impact of treatment plans on the lives of patients who live with chronic conditions. In 
addition, factors affecting medication-related burden should be taken into consideration 
when designing tailored interventions to reduce this burden.  
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Appendix A: The Living with Medicines Questionnaire: English version (LMQ) 
 
LMQ 
Living with Medicines Questionnaire 
 
 
Medicines and Your Day-to-Day Life 
 
Health Center code: 
Patient Code: 
Date: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LMQ© Version 3 2015 
This questionnaire seeks your views and opinions about the prescribed medicines 
you use and how they affect your life. 
Medicines include tablets, creams, inhalers, liquids, injections and so on. 
You may be using more than one medicine, please think about ALL your medicines 
when completing this questionnaire. 
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Please answer a few questions ABOUT YOU AND YOUR MEDICINES  
1. How many prescription medicines do you use regularly?     
Please write the TOTAL number of medicines here:                      
Medicines include tablets, capsules, creams, inhalers, inhalers, liquids, eye drops and so on. Count each 
different prescription as one medicine. 
2. Which type of medicines do you use regularly? You may tick one or both options  
              Tablets/Capsules                                                                             Any other type   
3. How often do you use your medicine(s)? You may tick one or more options  
         Once per day                            Twice per day                   Three times per day 
 More than three times per day                                                         Other, please 
specify……………………………………………   
4. Do you pay for your prescriptions?            Yes                                    No                                 
5. Does someone help you with using your medicines?          Yes               No                                
 If you answered yes, who helps you?            
6. Are you:                     Male                                    Female    
7. What is your age? Please write it here in years            
8. What is your nationality? 
Qatar Egypt Jordan Palestine Lebanon Sudan Yemen Syria Philippines India Pakistan Other, 
please 
indicate 
            
 
9. What is the highest level of education you have completed?   
        School                         Technical College/Apprenticeship                         University                Other  
10. What is your employment status?           
           Employed                     Unemployed                         Retired                               Full-time student
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The following statements cover different aspects of using medicines.    
Please read each statement carefully and tick the response box that is closest to your personal opinion. 
Please tick only one box for each statement. 
 
 Strongly 
agree 
Agree Neutral 
opinion 
Disagree Strongly 
disagree 
1. I find getting my prescriptions from the doctor difficult.       
2. I find getting my medicines from the pharmacist difficult.        
3. I am satisfied with the effectiveness of   my medicines.       
4. I am comfortable with the times I should take my medicines.      
5. I worry about paying for my medicines.      
 
 Strongly 
agree 
Agree Neutral 
opinion 
Disagree Strongly 
disagree 
6.  I worry that I have to take several medicines at the same time.      
      
7. I trust the judgement of my doctor(s) in choosing medicines for 
me.   
     
8. I would like more say in the brands of medicines I use.      
9. I feel I need more information about my medicines.      
10. I am concerned that I may forget to take my medicines.      
 
 Strongly 
agree 
Agree Neutral 
opinion 
Disagree Strongly 
disagree 
11. I can vary the dose of the medicines I take.      
12. I am concerned about possible damaging long term effects of 
taking medicines. 
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 Strongly 
agree 
Agree Neutral 
opinion 
Disagree Strongly 
disagree 
13. I can choose whether or not to take my medicines.      
14. My doctor(s) listen to my opinions about my medicines.      
15.    My medicines prevent my condition getting worse.      
16. I am concerned that I am too reliant on my medicines.      
17. I am concerned that my medicines interact with my nutritional 
habits (other foods - alcohol drinks). 
     
18. I worry that my medicines may interact with each other.      
19. My medicines interfere with my social or leisure activities.      
 
 Strongly 
agree 
Agree Neutral 
opinion 
Disagree Strongly 
disagree 
20. My doctor(s) takes my concerns about side effects seriously.      
21. The side effects I get are sometimes worse than the problem 
for which I take medicines. 
     
22. The side effects I get from my medicines interfere with my day-
to-day life (e.g. work, housework, sleep). 
     
23. I have to put a lot of planning and thought into taking my 
medicines. 
     
24. I get enough information about my medicines from my 
doctor(s). 
     
 
 Strongly 
agree 
Agree Neutral 
opinion 
Disagree Strongly 
disagree 
25. My medicines live up to my expectations.      
26.  I can vary the times I take my medicines.      
27. It is easy to keep to my medicines routine.      
28. Taking medicines affects my driving.      
29. I find using my medicines difficult.      
30. The side effects I get from my medicines are bothersome.      
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31. I sometimes have to choose between buying basic essentials 
or medicines. 
     
 
 Strongly 
agree 
Agree Neutral 
opinion 
Disagree Strongly 
disagree 
32. My medicines allow me to live my life as I want to.      
33. I have to pay more than I can afford for my medicines.      
34. The health professionals providing my care know enough 
about me and my medicines. 
     
35. My medicines interfere with my social relationships.      
36. Taking medicines causes me problems with daily tasks (such 
as work, housework, hobbies). 
     
 
 
 Strongly 
agree 
Agree Neutral 
opinion 
Disagree Strongly 
disagree 
37. My medicines interfere with my sexual life.      
38. The side effects I get from my medicines adversely 
affect my well-being. 
     
39. My medicines are working.      
40. The side effects are worth it for the benefits I get from 
my medicines. 
     
41. My life revolves around using my medicines      
 
 124 
 
 
The question below seeks your OVERALL OPINION about ALL your prescribed medicines.    
Please mark on the line with an ‘X’ at the position that best reflects your opinion.    
1. Overall, how much of a burden do you feel your medicines are to you? 
             
 
    
2. If you have any other views about how your medicines affect your day-to-day life, 
please describe them here.    
 
 
 
 
 
 
 
 
 
 
0 
1 2 3 4 5 6 7 8 9 
10 
No burden at all 
 
Extreme burdensome 
 
  
 )RA-QML( noisrev cibarA :eriannoitseuQ senicideM htiw gniviL ehT :B xidneppA
  مع الأدوية  استبيان التعايش QML    
                                                                    
                     
  
   
 
 الأدوية وحياتك
  اليومية 
  
  
 :edoc ertneC htlaeH
 :edoC tneitaP
 :etaD
  
  
  
 
 
 
 
 
 
 
 
 
 
  
 وآرائك حول الأدوية الموصوفة التي نظركصول على وجهات هذا الاستبيان للح يهدف
 .حياتكوكيف تؤثر على  تتناولها
 
 ، والحقن، وأجهزة الاستنشاق والسوائلوتشمل الأدوية الأقراص، والكريمات
 .خلافهو 
 
وقت الإجابة على هذا  بكل أدويتكربما تستخدم أكثر من دواء، الرجاء التفكير 
 .الاستبيان
  
 0       
  لأدويةامع  التعايشإستبيان  -لأدوية وحياتك اليوميةا
  
،
ً
 يرجى منك الاجابة على بعض الأسئلة المتعلقة بك وبأدويتكبداية
 ؟           الرجاء كتابة عدد الأدوية التي تتناولها هنا كم عدد الأدوية التي تتناولها بإنتظام -1
 وخلافه ، والقطرات العينيةالكريمات، وأجهزة الاستنشاق والسوائل، و ، والكبسولاتتشمل الأدوية الأقراص
 احسب كل وصفة دواء مختلفة كدواء واحد
 :يمكن اختيار واحد أو أوكثر من الخيارات التاليةتي تتناولها بانتظام؟ ما نوع الأدوية ال -2
 أي نوع آخر                                حبوب/ كبسولات            
؟  -3
ً
 :يمكن اختيار واحد أو أوكثر من الخيارات التاليةكم مرة تتناول أدويتك يوميا
 ثلاثة في اليوم أكثر من        ثلاث مرات في اليوم                                  مرتين في اليوم                                                                       مرة في اليوم          
 أخرى، الرجاء كتابتها هنا .....................................
 لاتدفع ثمن أدويتك الموصوفة؟              نعم                             هل -4
 لاأدويتك؟       نعم                         هل يساعدك أحد في استخدام -5
 موظف رعاية                           أحد  الأقارب             زوج                               الذي يساعدك في استخدام أدويتك؟   فمن  ،إذا أجبت بنعم
 يرجى كتابة من يساعدك هنا __________________________________________، آخرون                       إذا أجبت بـ(آخرون) 
       أنثى             ذكر                                                     أنت ؟        هل  -6
                   الرجاء كتابة عمرك بالسنوات هنا؟    هو عمرك:ما  -7
 ما هي جنسيتك ؟ -8
 
 ماهو أعلى مستوى تعليمي وصلت إليه؟ -9
   أخرى                                        جامعة                                                 مدرسة                                     كلية مهنية/تدريب مهني           
 طالب بدوام كامل                              متقاعد أعمل                                 لا أعمل         هو وضعك الوظيفي؟            ما  -01
، الرجاء أخرى  باكستان الهند الفلبين سوريا اليمن السودان لبنان فلسطين الأردن مصر قطر
 كتابتها
            
  
 ةلأدويامع  التعايشإستبيان  -لأدوية وحياتك اليوميةا
 تغطي الجمل التالية الجوانب المختلفة لاستخدام الأدوية.         
. يرجى اختيار مربع واحد فقط لكل وضع علامة في مربع الإجابة الأقرب إلى رأيك الشخص ي، وقراءة كل جملة بعناية الرجاء 
 جملة.
  أوافق     لا أوافق بشدة  أوافق بشدة  أوافق     رأي محايد  لا                                                                                 
 صعبًا من الطبيب وصفات دوائيأجد أن الحصول على  .1
 الصيدلي صعبًامن  أدويتيأجد أن الحصول على   .2
 فعالية أدويتي أنا راٍض عن  .3
 أن أتناول الأدوية في الأوقات المحددة لها أتقبلإنني   .4
 لقاء أدويتي أن أدفعيقلقني  .5
                                                                                          
  أوافق     لا أوافق بشدة  أوافق بشدة  أوافق     رأي محايد  لا                                                                          
 في نفس الوقت عدة أدويةيقلقني تناول   .6
 ختيار أدويتيبرأي طبيبي في ا أثق  .7
 في اختيار الاسم التجاري للدواء دور أكبرأود أن يكون لي  .8
                                                       أستخدمه الذي 
 معلومات أكثرأشعر أحيانا ًبالحاجة للحصول على   .9
 عن أدويتي 
 تناول أدويتي أنسىمن أنني قد  ينتابني القلق .01
 
 أوافق     لا أوافق بشدة  ق     رأي محايد  لافأوافق بشدة  أوا                                                                          
 حاجتيالأدوية التي أتناولها وفق  تغيير جرعةيمكنني   .11
 من تناول الأدوية الآثار الضارة المحتملةإزاء  القلق ينتابني .21
 المدى البعيدعلى 
  أوعدم تناولها تناول أدويتي بين الاختيارأستطيع   .31
 طبيبي إلى آرائي بشأن أدويتييستمع  .41
  أدويتي حالتي الصحية من أن تسوء تمنع .51
 على أدويتيالتام إعتمادي  يقلقني  .61
 عاداتي الغذائيةادويتي مع  تفاعليقلقني احتمال   .71
 )أخرى أطعمة كحولية، مشروبات(  
  
  
  لأدويةامع  التعايشستبيان ا -لأدوية وحياتك اليوميةا
 
 وضع علامة في مربع الإجابة الأقرب إلى رأيك الشخص يالرجاء  
                                                                                                                                                                                                                                                                                                     فق بشدةأوافق     لا أوا  أوافق بشدة  أوافق     رأي محايد  لا                                                                               
 
               تتفاعل أدويتي مع بعضها البعضيقلقني أن  .81
 والترفيهيةأنشاطاتي الاجتماعية تؤثر أدويتي على   .91
 حول التأثيرات الجانبية للدواء بما يقلقنييهتم طبيبي   .02
 أسوأ من المشكلة الصحيةللدواء تكون أحيانا ً الآثار الجانبية  .12
 أجلها من الدواء أتناول التي 
 الناتجة عن أدويتي تؤثر على حياتي اليومية الآثار الجانبية  .22
 ، النوم)الأعمال المنزلية(مثل: العمل، 
 مني التخطيط والتفكيريتطلب تناول أدويتي الكثير من  .32
 من طبيبي عن أدويتي  معلومات كافيةأحصل على   .42
 
  أوافق     لا أوافق بشدة  أوافق بشدة  أوافق     رأي محايد  لا                                                                            
 منها توقعاتيتحقق  أدويتي  .52
 تناول أدويتي إذا أردت ذلك تغيير مواعيدأستطيع  .62
  ناول أدويتيالحفاظ على روتين ت السهلمن   .72
 على قيادة السيارةتناول الأدوية يؤثر على قدرتي   .82
  صعبا ً  أدويتي أمراً  استخدامأجد  .92
 مزعجةالآثار الجانبية الناتجة عن أدويتي   .03
 أحيانا ًبين شراء الحاجات الأساسية أو الأدوية الاختيارعلي   .13
 
 أوافق     لا أوافق بشدة  أوافق بشدة  أوافق     رأي محايد  لا                                                                      
 كما أريد أعيش حياتيأدويتي تسمح لي بأن  .23
 على شراء الأدوية يفوق مقدرتي إنفاقهما يتوجب علي  .33
 اختصاصيو الرعاية الصحية الذين يوفرون الرعاية لي .43
  أدويتي وعن عني يكفي مايعرفون 
 علاقاتي الاجتماعيةتؤثر أدويتي على   .53
  أنشطتي اليوميةيسبب لي تناول الأدوية مشاكل مع   .63
 (كالعمل، والاعمال المنزلية والهوايات)
 
            
  
  
 لأدويةامع  التعايش ستبيانا -الأدوية وحياتك اليومية
 
 إلى رأيك الشخص ي وضع علامة في مربع الإجابة الأقربالرجاء  
  أوافق     لا أوافق بشدة  أوافق بشدة  أوافق     رأي محايد  لا                                                                                 
  حياتي الجنسيةأدويتي تؤثر على  .73
 الناتجة عن أدويتي تؤثر سلبا ًعلى صحتي الآثار الجانبية  .83
 فعالةأدويتي  .93
  الآثار الجانبيةالفوائد التي أحصل عليها من الدواء تفوق  .04
 حياتيأدويتي تشغل حيزا ًكبيرا ًمن   .14
  
 يهدف السؤال التالي لمعرفة رأيك الإجمالي عن كل أدويتك الموصوفة.
 في الموقع الأقرب الذي يدل على رأيك:  Xوضع علامة  الرجاء
 
 بشكل عام، كيف تشعر بالعبء الذي تشكله أدويتك؟ -
 
 01                                                                                                                     0                 
تشكل          9        8         7        6        5        4          3       2         1                     لا تشكل عبئا  
 عبئا  كبيرا  
 
 
 
 
 
 
 
 اذا كانت لديك أية آراء اخرى حول مدى تأثير أدويتك على حياتك اليومية، يرجى ذكرها هنا
 
 
 
 
 
 
 
 
 
 
  
Appendix C: Adherence to Refills and Medications Scale (ARMS) – English version 
ADHERENCE TO REFILLS AND MEDICATIONS SCALE (ARMS) 
I would like to ask you how often you actually miss taking your medicines. There are no right or wrong answers. For each question, please 
answer “none of the time,” “some of the time,” “most of the time,” or “all of the time.” 
 None Some Most All 
1. How often do you forget to take your medicine? 1 2 3 4 
2. How often do you decide not to take your medicine? 1 2 3 4 
3. How often do you forget to get prescriptions filled? 1 2 3 4 
4. How often do you run out of medicine? 1 2 3 4 
5. How often do you skip a dose of your medicine before you go to the doctor? 1 2 3 4 
6. How often do you miss taking your medicine when you feel better? 1 2 3 4 
7. How often do you miss taking your medicine when you feel sick? 1 2 3 4 
8. How often do you miss taking your medicine when you are careless? 1 2 3 4 
9. How often do you change the dose of your medicines to suit your needs (like 1 2 3 4 
when you take more or less pills than you’re supposed to)? 
10. How often do you forget to take your medicine when you are supposed to 1 2 3 4 
take it more than once a day? 
11. How often do you put off refilling your medicines because they cost too much money?                1          2                 3       4 
12. How often do you plan ahead and refill your medicines before they run out?         1          2          3          4 
  
 noisrev cibarA – )SMRA( elacS snoitacideM dna sllifeR ot ecnerehdA :D xidneppA
 
 تقييم الالتزام بتناول الأدوية وإعادة صرفها
الرجاء اختيار ئة. إجابة صحيحة أو خاط لأدويتك بالفعل. ليس هناك تكرار عدم تناولك مدى عن أود أن أسألك
 ".دائما  "، أو " معظم الأحيانبعض الأحيان"، "" أبدا "،، "الإجابة من بين
 
بعض  أبدا   
 الأحيان
معظم 
 الأحيان
 دائما  
 ماهو مدى تكرار نسيانك لأخذ أدويتك؟. 1
 
 4 3 2 1
 دوائك؟ بعدم تناول ماهو مدى تكرار قرارك. 2
 
 4 3 2 1
 ؟أدويتكرف صل ماهو مدى تكرار نسيانك. 3
 
 4 3 2 1
 ؟التي بحوزتك أدويتك ماهو مدى تكرار نفاذ. 4
 
 4 3 2 1
 جرعة من دوائك قبل زيارة طبيبك؟ ماهو مدى تكرار تركك. 5
 
 4 3 2 1
حالتك  بتحسن تناول دوائك لشعورك ماهو مدى تكرار تغاضيك عن. 6
 ؟الصحية
 
 4 3 2 1
سوء حالتك ب شعوركتناول دوائك ل ماهو مدى تكرار تغاضيك عن. 7
 ؟الصحية
 
 4 3 2 1
 ؟ماهو مدى تكرار تغاضيك عن تناول أدويتك بسبب الإهمال. 8
 
 4 3 2 1
 ؟ماهو مدى تكرار تغييرك لجرعة الدواء لتناسب احتياجاتك. 9
 طلوب منكأقل أو أكثر من الم (مثلا، عندما تتناول أقراص من الدواء
 )هتناول
 4 3 2 1
 الهتناو يفترض عليك التي أدويتكتناول ل سيانكماهو مدى تكرار ن. 01
 ؟يوميا  أكثر من مرة 
 
 4 3 2 1
إعادة صرف أدويتك لأنها تكلف الكثير من أجيل تماهو مدى تكرار . 11
 المال؟
 
 4 3 2 1
 مسبقا  لإعادة صرف أدويتك قبل نفاذها؟ كطيتخطماهو مدى تكرار . 21
 
 4 3 2 1
 
  
Appendix E: Data collection form 
Patient Data Form (to be filled from Medical Records and/or patients’ 
interviews)  
 
 
Patient HealthCare center Code: 
 
 
Patient research ID:  
 
 
Date of interview/ PHCC visit:  
 
 
Patient mobile:              
                                                       
 
Patient email address if any:  
 
 
 
Inclusion Criteria  (Must ALL be “Yes” to be included) Yes No 
1. At least 18 years of age    
2. Communicates in English and/or Arabic   
3. Has a chronic condition for at least 6 months at the time of the interview   
 
Sociodemographic  information 
 
Marital status □ Married 
□ Single 
□ Divorcee 
□ Widowed 
Education level  Less than primary school 
 Primary or middle school 
 Secondary or high school only  
 Technical College/Apprenticeship 
 University degree  
 Post graduate University degree 
 
Medical conditions 
 
DM diagnosis 
duration 
 
Comorbidities (all 
that apply) 
□ Hypertension 
□ Dyslipidemia 
□ Hyperlipidemia 
□ Vit. D deficiency 
  
□ Obesity 
□ Depression 
□ Other (Please specify): 
 
Smoking History 
 
Cigarette smoking 
 
□ Current smoker: ------------- cigarettes per day 
□ Former smoker 
□ Non-smoker 
Shisha smoking 
 
□ Current daily shisha smoking 
□ Current social shisha smoking 
□ Former shisha smoker 
□ Non smoker 
 
 
Medications Intake 
 
Prescribed 
Medications 
 
Medication list Regimen Date of last refill 
 
 
 
 
 
 
 
 
 
 
lifestyle changes  □ None 
□ Exercise  
□ Exercise and healthy diet 
 
Clinical indicators (last values) 
 
HbA1c%  
 
BMI  
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